{"id":702221,"date":"2026-06-12T13:51:13","date_gmt":"2026-06-12T11:51:13","guid":{"rendered":"https:\/\/www.dynseo.com\/sclerose-en-plaques-tout-comprendre-sur-cette-maladie-neurologique-2\/"},"modified":"2026-06-12T13:56:19","modified_gmt":"2026-06-12T11:56:19","slug":"multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease","status":"publish","type":"post","link":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/","title":{"rendered":"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Article HTML&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row admin_label=&#8221;Contenu&#8221; _builder_version=&#8221;4.16&#8243; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code admin_label=&#8221;HTML import\u00e9&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<style type=\"text\/css\">\n:root {\n    --blue: #5e5ed7;\n    --blue-dark: #5268c9;\n    --teal: #a9e2e4;\n    --yellow: #ffeca7;\n    --pink: #e73469;\n    --white: #ffffff;\n    --light-bg: #f8f9ff;\n    --text: #2d2d4e;\n    --text-light: #6b6b8a;\n    --border-radius: 16px;\n    --shadow: 0 4px 24px rgba(94,94,215,0.10);\n    --shadow-card: 0 2px 16px rgba(94,94,215,0.08);\n  }\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Montserrat:wght@400;500;600;700;800&family=Poppins:wght@300;400;500;600&display=swap');<\/p>\n<p>  * { box-sizing: border-box; margin: 0; padding: 0; }\n.dbi-art-b0224d { font-family: 'Poppins', sans-serif; color: var(--text); background: #fff; line-height: 1.75; font-size: 16px; }\n.dbi-art-b0224d h1, .dbi-art-b0224d h2, .dbi-art-b0224d h3, .dbi-art-b0224d h4 { font-family: 'Montserrat', sans-serif; }\n.dbi-art-b0224d .hero {\n    background: linear-gradient(135deg, var(--blue) 0%, var(--blue-dark) 60%, #3d4fa8 100%);\n    color: white; padding: 72px 24px 56px; text-align: center; position: relative; overflow: hidden;\n  }\n.dbi-art-b0224d .hero::before {\n    content: ''; position: absolute; inset: 0;\n    background: url(\"data:image\/svg+xml,%3Csvg width='60' height='60' viewBox='0 0 60 60' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cg fill='none' fill-rule='evenodd'%3E%3Cg fill='%23ffffff' fill-opacity='0.04'%3E%3Ccircle cx='30' cy='30' r='20'\/%3E%3C\/g%3E%3C\/g%3E%3C\/svg%3E\");\n    pointer-events: none;\n  }\n.dbi-art-b0224d .hero-tag { display: inline-block; background: rgba(255,255,255,0.18); border: 1px solid rgba(255,255,255,0.3); color: white; padding: 6px 18px; border-radius: 50px; font-size: 13px; font-weight: 600; letter-spacing: 1px; text-transform: uppercase; margin-bottom: 20px; }\n.dbi-art-b0224d .hero h1 { font-size: clamp(26px, 4vw, 44px); font-weight: 800; line-height: 1.2; max-width: 820px; margin: 0 auto 20px; }\n.dbi-art-b0224d .hero-sub { font-size: 17px; opacity: 0.88; max-width: 620px; margin: 0 auto 32px; font-weight: 300; }\n.dbi-art-b0224d .hero-meta { display: flex; justify-content: center; gap: 24px; flex-wrap: wrap; font-size: 13px; opacity: 0.75; }\n.dbi-art-b0224d .hero-meta span { display: flex; align-items: center; gap: 6px; }\n.dbi-art-b0224d .container { max-width: 860px; margin: 0 auto; padding: 0 24px; }\n.dbi-art-b0224d .section { padding: 52px 0 40px; }\n.dbi-art-b0224d .stats-bar { background: var(--light-bg); border-bottom: 1px solid rgba(94,94,215,0.08); padding: 32px 24px; }\n.dbi-art-b0224d .stats-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(160px, 1fr)); gap: 16px; max-width: 860px; margin: 0 auto; }\n.dbi-art-b0224d .stat-item { text-align: center; padding: 20px 12px; background: white; border-radius: var(--border-radius); box-shadow: var(--shadow-card); }\n.dbi-art-b0224d .stat-num { font-family: 'Montserrat', sans-serif; font-size: 30px; font-weight: 800; color: var(--blue); display: block; }\n.dbi-art-b0224d .stat-label { font-size: 12px; color: var(--text-light); font-weight: 500; margin-top: 4px; display: block; }\n.dbi-art-b0224d .intro-block { border-left: 4px solid var(--blue); background: rgba(94,94,215,0.04); padding: 24px 28px; border-radius: 0 var(--border-radius) var(--border-radius) 0; margin: 36px 0; }\n.dbi-art-b0224d .intro-block p { font-size: 17px; line-height: 1.8; color: var(--text); }\n.dbi-art-b0224d h2 { font-size: clamp(20px, 3vw, 28px); font-weight: 800; color: var(--blue); margin: 48px 0 20px; padding-bottom: 12px; border-bottom: 2px solid var(--teal); }\n.dbi-art-b0224d h3 { font-size: 18px; font-weight: 700; color: var(--blue-dark); margin: 32px 0 14px; }\n.dbi-art-b0224d p { margin-bottom: 18px; color: var(--text); }\n.dbi-art-b0224d .cards-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(240px, 1fr)); gap: 20px; margin: 28px 0; }\n.dbi-art-b0224d .card { background: white; border-radius: var(--border-radius); padding: 28px 24px; box-shadow: var(--shadow-card); border: 1px solid rgba(94,94,215,0.08); transition: transform 0.2s, box-shadow 0.2s; }\n.dbi-art-b0224d .card:hover { transform: translateY(-3px); box-shadow: var(--shadow); }\n.dbi-art-b0224d .card-icon { width: 48px; height: 48px; border-radius: 12px; display: flex; align-items: center; justify-content: center; font-size: 22px; margin-bottom: 16px; }\n.dbi-art-b0224d .card-icon.blue { background: rgba(94,94,215,0.1); }\n.dbi-art-b0224d .card-icon.teal { background: rgba(169,226,228,0.3); }\n.dbi-art-b0224d .card-icon.yellow { background: rgba(255,236,167,0.5); }\n.dbi-art-b0224d .card-icon.pink { background: rgba(231,52,105,0.1); }\n.dbi-art-b0224d .card h4 { font-size: 15px; font-weight: 700; color: var(--text); margin-bottom: 10px; font-family: 'Montserrat', sans-serif; }\n.dbi-art-b0224d .card p { font-size: 14px; color: var(--text-light); margin: 0; line-height: 1.65; }\n.dbi-art-b0224d .numbered-card { display: flex; gap: 20px; align-items: flex-start; background: white; border-radius: var(--border-radius); padding: 24px; box-shadow: var(--shadow-card); border: 1px solid rgba(94,94,215,0.07); margin-bottom: 16px; }\n.dbi-art-b0224d .num-badge { min-width: 44px; height: 44px; border-radius: 50%; background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; font-family: 'Montserrat', sans-serif; font-weight: 800; font-size: 17px; display: flex; align-items: center; justify-content: center; flex-shrink: 0; }\n.dbi-art-b0224d .num-content h4 { font-size: 15px; font-weight: 700; color: var(--text); margin-bottom: 8px; font-family: 'Montserrat', sans-serif; }\n.dbi-art-b0224d .num-content p { font-size: 14px; color: var(--text-light); margin: 0; }\n.dbi-art-b0224d .table-wrap { overflow-x: auto; margin: 28px 0; border-radius: var(--border-radius); box-shadow: var(--shadow-card); }\n.dbi-art-b0224d table { width: 100%; border-collapse: collapse; font-size: 14px; }\n.dbi-art-b0224d thead tr { background: linear-gradient(90deg, var(--blue), var(--blue-dark)); color: white; }\n.dbi-art-b0224d thead th { padding: 16px 18px; text-align: left; font-family: 'Montserrat', sans-serif; font-weight: 700; }\n.dbi-art-b0224d tbody tr:nth-child(even) { background: var(--light-bg); }\n.dbi-art-b0224d tbody tr:nth-child(odd) { background: white; }\n.dbi-art-b0224d tbody td { padding: 14px 18px; color: var(--text); border-bottom: 1px solid rgba(94,94,215,0.06); }\n.dbi-art-b0224d tbody tr:last-child td { border-bottom: none; }\n.dbi-art-b0224d .badge { display: inline-block; padding: 3px 10px; border-radius: 50px; font-size: 12px; font-weight: 600; }\n.dbi-art-b0224d .badge-blue { background: rgba(94,94,215,0.12); color: var(--blue); }\n.dbi-art-b0224d .badge-teal { background: rgba(169,226,228,0.4); color: #2a8a8c; }\n.dbi-art-b0224d .badge-yellow { background: rgba(255,236,167,0.8); color: #a87800; }\n.dbi-art-b0224d .badge-pink { background: rgba(231,52,105,0.1); color: var(--pink); }\n.dbi-art-b0224d .tip-box { background: var(--yellow); border-radius: var(--border-radius); padding: 22px 26px; margin: 28px 0; display: flex; gap: 16px; align-items: flex-start; }\n.dbi-art-b0224d .tip-box .icon { font-size: 22px; flex-shrink: 0; margin-top: 2px; }\n.dbi-art-b0224d .tip-box p { font-size: 15px; margin: 0; color: var(--text); }\n.dbi-art-b0224d .tip-box strong { color: var(--blue-dark); }\n.dbi-art-b0224d .warning-box { background: rgba(231,52,105,0.07); border-left: 4px solid var(--pink); border-radius: 0 var(--border-radius) var(--border-radius) 0; padding: 20px 24px; margin: 28px 0; }\n.dbi-art-b0224d .warning-box p { font-size: 15px; margin: 0; color: var(--text); }\n.dbi-art-b0224d .quote-box { background: rgba(94,94,215,0.06); border-left: 4px solid var(--blue); border-radius: 0 var(--border-radius) var(--border-radius) 0; padding: 22px 28px; margin: 28px 0; }\n.dbi-art-b0224d .quote-box p { font-size: 16px; font-style: italic; color: var(--text); margin: 0; }\n.dbi-art-b0224d .quote-box cite { display: block; margin-top: 10px; font-size: 13px; color: var(--text-light); font-style: normal; font-weight: 600; }\n.dbi-art-b0224d .checklist { background: white; border-radius: var(--border-radius); padding: 28px 32px; box-shadow: var(--shadow-card); margin: 28px 0; list-style: none; }\n.dbi-art-b0224d .checklist li { padding: 10px 0; border-bottom: 1px solid rgba(94,94,215,0.07); font-size: 15px; display: flex; gap: 12px; align-items: flex-start; }\n.dbi-art-b0224d .checklist li:last-child { border-bottom: none; }\n.dbi-art-b0224d .checklist li::before { content: '\u2714'; color: var(--blue); font-weight: 700; flex-shrink: 0; margin-top: 1px; }\n.dbi-art-b0224d .cta-formation { background: linear-gradient(135deg, var(--blue) 0%, var(--blue-dark) 100%); border-radius: var(--border-radius); padding: 36px 32px; margin: 36px 0; color: white; display: flex; gap: 24px; align-items: center; flex-wrap: wrap; }\n.dbi-art-b0224d .cta-formation .cta-icon { font-size: 40px; flex-shrink: 0; }\n.dbi-art-b0224d .cta-formation h4 { font-size: 18px; font-weight: 800; font-family: 'Montserrat', sans-serif; margin-bottom: 8px; color: white; }\n.dbi-art-b0224d .cta-formation p { font-size: 14px; opacity: 0.88; margin: 0 0 16px; color: white; }\n.dbi-art-b0224d .btn-white { display: inline-block; background: white; color: var(--blue); font-family: 'Montserrat', sans-serif; font-weight: 700; font-size: 14px; padding: 12px 26px; border-radius: 50px; text-decoration: none; transition: transform 0.2s, box-shadow 0.2s; }\n.dbi-art-b0224d .btn-white:hover { transform: translateY(-2px); box-shadow: 0 8px 20px rgba(0,0,0,0.15); }\n.dbi-art-b0224d .cta-outil { background: var(--teal); border-radius: var(--border-radius); padding: 28px 28px; margin: 28px 0; display: flex; gap: 20px; align-items: center; flex-wrap: wrap; }\n.dbi-art-b0224d .cta-outil .cta-icon { font-size: 36px; flex-shrink: 0; }\n.dbi-art-b0224d .cta-outil h4 { font-size: 16px; font-weight: 700; font-family: 'Montserrat', sans-serif; color: var(--text); margin-bottom: 6px; }\n.dbi-art-b0224d .cta-outil p { font-size: 14px; color: var(--text); margin: 0 0 14px; }\n.dbi-art-b0224d .btn-blue { display: inline-block; background: var(--blue); color: white; font-family: 'Montserrat', sans-serif; font-weight: 700; font-size: 13px; padding: 10px 22px; border-radius: 50px; text-decoration: none; transition: transform 0.2s; }\n.dbi-art-b0224d .btn-blue:hover { transform: translateY(-2px); }\n.dbi-art-b0224d .two-cols { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 28px 0; }\n@media (max-width: 600px) {\n.dbi-art-b0224d .two-cols { grid-template-columns: 1fr; }\n}\n.dbi-art-b0224d .col-block { background: white; border-radius: var(--border-radius); padding: 24px; box-shadow: var(--shadow-card); }\n.dbi-art-b0224d .col-block h4 { font-family: 'Montserrat', sans-serif; font-size: 15px; font-weight: 700; margin-bottom: 14px; display: flex; gap: 10px; align-items: center; }\n.dbi-art-b0224d .col-block ul { list-style: none; padding: 0; }\n.dbi-art-b0224d .col-block ul li { font-size: 14px; padding: 7px 0; border-bottom: 1px solid rgba(94,94,215,0.06); color: var(--text); padding-left: 18px; position: relative; }\n.dbi-art-b0224d .col-block ul li::before { content: '\u2192'; position: absolute; left: 0; color: var(--blue); font-weight: 700; }\n.dbi-art-b0224d .col-block ul li:last-child { border-bottom: none; }\n.dbi-art-b0224d .highlight-box { background: linear-gradient(135deg, rgba(169,226,228,0.3), rgba(255,236,167,0.3)); border-radius: var(--border-radius); padding: 28px; margin: 28px 0; border: 1px solid rgba(169,226,228,0.5); }\n.dbi-art-b0224d .highlight-box h4 { font-family: 'Montserrat', sans-serif; font-size: 16px; font-weight: 700; color: var(--blue); margin-bottom: 12px; }\n.dbi-art-b0224d .highlight-box p { font-size: 15px; margin: 0; }\n.dbi-art-b0224d .timeline { margin: 28px 0; position: relative; }\n.dbi-art-b0224d .timeline::before { content: ''; position: absolute; left: 24px; top: 0; bottom: 0; width: 3px; background: linear-gradient(180deg, var(--blue), var(--teal)); border-radius: 3px; }\n.dbi-art-b0224d .timeline-item { display: flex; gap: 20px; margin-bottom: 24px; position: relative; }\n.dbi-art-b0224d .timeline-dot { min-width: 48px; height: 48px; border-radius: 50%; background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; display: flex; align-items: center; justify-content: center; font-size: 18px; flex-shrink: 0; z-index: 1; box-shadow: 0 4px 12px rgba(94,94,215,0.3); }\n.dbi-art-b0224d .timeline-content { background: white; border-radius: var(--border-radius); padding: 20px 24px; box-shadow: var(--shadow-card); flex: 1; border: 1px solid rgba(94,94,215,0.07); }\n.dbi-art-b0224d .timeline-content h4 { font-family: 'Montserrat', sans-serif; font-size: 15px; font-weight: 700; color: var(--blue); margin-bottom: 8px; }\n.dbi-art-b0224d .timeline-content p { font-size: 14px; color: var(--text-light); margin: 0; }\n.dbi-art-b0224d .profil-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 16px; margin: 28px 0; }\n.dbi-art-b0224d .profil-card { background: white; border-radius: var(--border-radius); padding: 22px 18px; box-shadow: var(--shadow-card); text-align: center; border-top: 4px solid var(--blue); }\n.dbi-art-b0224d .profil-card .emoji { font-size: 32px; margin-bottom: 10px; display: block; }\n.dbi-art-b0224d .profil-card h4 { font-size: 14px; font-weight: 700; font-family: 'Montserrat', sans-serif; margin-bottom: 8px; color: var(--blue); }\n.dbi-art-b0224d .profil-card p { font-size: 13px; color: var(--text-light); margin: 0; line-height: 1.6; }\n.dbi-art-b0224d .faq-section { background: var(--light-bg); padding: 52px 24px; margin-top: 52px; }\n.dbi-art-b0224d .faq-section h2 { color: var(--blue); border-color: var(--teal); }\n.dbi-art-b0224d .faq-item { background: white; border-radius: var(--border-radius); padding: 24px 28px; margin-bottom: 14px; box-shadow: var(--shadow-card); }\n.dbi-art-b0224d .faq-item h4 { font-family: 'Montserrat', sans-serif; font-size: 16px; font-weight: 700; color: var(--blue); margin-bottom: 12px; display: flex; gap: 12px; align-items: flex-start; }\n.dbi-art-b0224d .faq-item h4 span { color: var(--teal); flex-shrink: 0; }\n.dbi-art-b0224d .faq-item p { font-size: 15px; margin: 0; color: var(--text); }\n.dbi-art-b0224d .conclusion { background: linear-gradient(135deg, rgba(94,94,215,0.08) 0%, rgba(169,226,228,0.15) 100%); border-radius: var(--border-radius); padding: 40px 36px; margin: 40px 0; text-align: center; }\n.dbi-art-b0224d .conclusion h2 { border: none; margin-top: 0; }\n.dbi-art-b0224d .conclusion p { font-size: 16px; max-width: 640px; margin: 0 auto 24px; }\n.dbi-art-b0224d .btn-cta { display: inline-block; background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; font-family: 'Montserrat', sans-serif; font-weight: 700; font-size: 15px; padding: 14px 32px; border-radius: 50px; text-decoration: none; box-shadow: 0 6px 20px rgba(94,94,215,0.3); transition: transform 0.2s, box-shadow 0.2s; }\n.dbi-art-b0224d .btn-cta:hover { transform: translateY(-3px); box-shadow: 0 10px 28px rgba(94,94,215,0.4); }\n.dbi-art-b0224d .article-footer { background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; padding: 40px 24px; text-align: center; }\n.dbi-art-b0224d .article-footer p { color: rgba(255,255,255,0.8); font-size: 14px; margin-bottom: 16px; }\n.dbi-art-b0224d .footer-links { display: flex; justify-content: center; gap: 20px; flex-wrap: wrap; }\n.dbi-art-b0224d .footer-links a { color: white; text-decoration: none; font-size: 13px; font-weight: 600; padding: 8px 18px; border: 1px solid rgba(255,255,255,0.3); border-radius: 50px; transition: background 0.2s; }\n.dbi-art-b0224d .footer-links a:hover { background: rgba(255,255,255,0.15); }\n@media (max-width: 640px) {\n.dbi-art-b0224d .cta-formation, .dbi-art-b0224d .cta-outil { flex-direction: column; }\n.dbi-art-b0224d .cards-grid { grid-template-columns: 1fr; }\n.dbi-art-b0224d .timeline::before { left: 20px; }\n}<\/p>\n<\/style>\n<div class=\"dbi-art-b0224d\">\n<!-- \u2550\u2550 HERO \u2550\u2550 --><\/p>\n<header class=\"hero\">\n<div class=\"hero-tag\">\ud83e\udde0 Neurological diseases \u00b7 Multiple sclerosis<\/div>\n<h1>Multiple sclerosis: understand everything<!\u2013- [et_pb_br_holder] -\u2013>about this neurological disease<\/h1>\n<pee class=\"hero-sub\">Causes, symptoms, progressive forms, diagnosis and management \u2014 a complete guide for patients, relatives and healthcare professionals<\/pee>\n<div class=\"hero-meta\">\n    <span>\ud83d\udcd6 Reading: ~22 min<\/span><br \/>\n    <span>\u2705 Updated 2026<\/span><br \/>\n    <span>\ud83d\udc69\u200d\u2695\ufe0f Patients, families &amp; caregivers<\/span>\n  <\/div>\n<\/header>\n<p><!-- \u2550\u2550 STATS \u2550\u2550 --><\/p>\n<div class=\"stats-bar\">\n<div class=\"stats-grid\">\n<div class=\"stat-item\">\n      <span class=\"stat-num\">120,000<\/span><br \/>\n      <span class=\"stat-label\">people affected in France<\/span>\n    <\/div>\n<div class=\"stat-item\">\n      <span class=\"stat-num\">3,000<\/span><br \/>\n      <span class=\"stat-label\">new cases diagnosed each year<\/span>\n    <\/div>\n<div class=\"stat-item\">\n      <span class=\"stat-num\">30 years<\/span><br \/>\n      <span class=\"stat-label\">average age at diagnosis<\/span>\n    <\/div>\n<div class=\"stat-item\">\n      <span class=\"stat-num\">2\u00d7<\/span><br \/>\n      <span class=\"stat-label\">more common in women<\/span>\n    <\/div>\n<\/p><\/div>\n<\/div>\n<p><!-- \u2550\u2550 CONTENT \u2550\u2550 --><br \/>\n<main class=\"container\"><\/p>\n<div class=\"intro-block\">\n    <pee>Multiple sclerosis (MS) is one of the most common neurological diseases among young adults. A chronic autoimmune disease of the central nervous system, it affects approximately 120,000 people in France and still raises many questions, fears, and misconceptions today. This comprehensive guide aims to help you deeply understand what MS really is: its biological mechanisms, its multiple clinical faces, the challenges of diagnosis, the treatments available in 2026, and above all, the concrete resources to support patients and their loved ones on a daily basis.<\/pee>\n  <\/div>\n<p>  <!-- \u2500\u2500 SECTION 1 \u2500\u2500 --><\/p>\n<h2>1. What is multiple sclerosis? Definition and mechanisms<\/h2>\n<pee>The term &#8220;multiple sclerosis&#8221; may seem mysterious. It actually refers to a precise anatomical reality: <strong>plaques of demyelination<\/strong> \u2014 that is, areas where the myelin, the protective sheath of nerve fibers, has been damaged \u2014 scattered throughout the brain and spinal cord. These scars (sclerosis) give the disease its name.<\/pee>\n<h3>1.1 Myelin: understanding why it&#8217;s central<\/h3>\n<pee>To understand MS, one must understand the role of myelin. This fatty substance surrounds axons (extensions of neurons) and acts as an insulating electrical cable: it accelerates and ensures the reliability of nerve impulse transmission. Without intact myelin, nerve signals slow down, disperse, or fail to reach their destination.<\/pee>\n<pee>In MS, the immune system mistakenly attacks this myelin \u2014 this is the definition of an autoimmune disease. Immune cells (mainly T lymphocytes) cross the blood-brain barrier and cause inflammation that gradually destroys the myelin sheath, and sometimes the axons themselves. The result: disturbances in the transmission of nerve signals, which manifest as the very varied symptoms characteristic of MS.<\/pee>\n<div class=\"highlight-box\">\n<h4>\ud83e\uddec MS: an autoimmune disease, not contagious<\/h4>\n<pee>MS is <strong>not contagious<\/strong>, does not transmit from one person to another and is <strong>not directly hereditary<\/strong> in the strict sense. It results from a complex interaction between a genetic predisposition (several genes involved, including HLA-DRB1) and triggering environmental factors. Having a parent with MS increases the risk, but does not make it certain.<\/pee>\n<\/div>\n<h3>1.2 Why &#8220;plaques&#8221;?<\/h3>\n<pee>The term &#8220;plaques&#8221; refers to the visible lesions on MRI \u2014 areas of demyelination that appear as white spots on brain images. These plaques are <strong>disseminated in space<\/strong> (they are found in several places in the brain and spinal cord) and <strong>disseminated in time<\/strong> (they appear at different times). This double dissemination \u2014 spatial and temporal \u2014 actually forms the basis of the modern diagnosis of MS.<\/pee>\n<p><!-- \u2500\u2500 SECTION 2 \u2500\u2500 --><\/p>\n<h2>2. The causes of MS: what research has identified<\/h2>\n<pee>After decades of research, multiple sclerosis is now better understood, even though no single definitive cause has been identified. MS results from an interaction between genetic, immunological, and environmental factors.<\/pee>\n<h3>2.1 Genetic factors<\/h3>\n<pee>MS is not a genetic disease in the classical sense \u2014 there is no unique &#8220;MS gene.&#8221; However, a genetic predisposition is clearly established. The risk of developing MS is about 0.1% in the general population, but rises to 2-3% if a first-degree relative is affected, and to 25-30% in monozygotic twins (identical twins). More than 200 genetic variants have been associated with susceptibility to MS, most involved in the regulation of the immune system.<\/pee>\n<h3>2.2 Environmental factors: the main suspects<\/h3>\n<div class=\"cards-grid\">\n<div class=\"card\">\n<div class=\"card-icon blue\">\u2600\ufe0f<\/div>\n<h4>Vitamin D deficiency<\/h4>\n<pee>Vitamin D plays a major immunoregulatory role. Regions far from the equator, with less sunshine, have a significantly higher prevalence of MS. Studies show that low vitamin D levels increase the risk of MS and are associated with higher disease activity.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon teal\">\ud83e\udda0<\/div>\n<h4>Epstein-Barr Virus (EBV)<\/h4>\n<pee>Very strong recent studies (notably on millions of American military personnel) establish a strong link between infection with the EBV (responsible for mononucleosis) and the development of MS. This mechanism is the subject of intense research in 2026.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon yellow\">\ud83d\udeac<\/div>\n<h4>Smoking<\/h4>\n<pee>Tobacco is a recognized risk factor, which increases both the likelihood of developing MS and its rate of progression. It also reduces the effectiveness of immunomodulatory treatments.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon pink\">\ud83e\uddeb<\/div>\n<h4>Gut microbiome<\/h4>\n<pee>Disruptions of the gut microbiome (dysbiosis) have been observed in MS patients. The link between the gut-brain axis and autoimmune inflammation is a major research area that could open new therapeutic avenues.<\/pee>\n    <\/div>\n<\/div>\n<div class=\"tip-box\">\n<div class=\"icon\">\ud83d\udca1<\/div>\n<pee><strong>The mystery of latitude:<\/strong> MS is significantly more common in Nordic countries (Scandinavia, Scotland, Canada) than in tropical countries. In France, the prevalence is higher in Alsace than in Corsica. This geographical distribution directs researchers towards sunlight, vitamin D, and infectious factors as keys to understanding the disease.<\/pee>\n  <\/div>\n<p>  <!-- \u2500\u2500 SECTION 3 \u2500\u2500 --><\/p>\n<h2>3. The different forms of MS<\/h2>\n<pee>MS is not a uniform disease. It presents in several evolving forms, which differ in their relapse profile, rate of progression, and therapeutic implications.<\/pee>\n<div class=\"table-wrap\">\n<table>\n<thead>\n<tr>\n<th>Form<\/th>\n<th>Evolving profile<\/th>\n<th>Frequency<\/th>\n<th>Treatment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Relapsing-remitting MS (RRMS)<\/strong><\/td>\n<td>Relapses with partial or total recovery between episodes<\/td>\n<td><span class=\"badge badge-pink\">85% of cases at diagnosis<\/span><\/td>\n<td>Very effective disease-modifying treatments available<\/td>\n<\/tr>\n<tr>\n<td><strong>Secondarily progressive MS (SPMS)<\/strong><\/td>\n<td>Initial relapsing phase, then continuous progression with or without relapses<\/td>\n<td><span class=\"badge badge-blue\">50% of RRMS after 10-15 years<\/span><\/td>\n<td>Limited but expanding options<\/td>\n<\/tr>\n<tr>\n<td><strong>Primarily progressive MS (PPMS)<\/strong><\/td>\n<td>Continuous progression from the start, without distinct relapses<\/td>\n<td><span class=\"badge badge-yellow\">10-15% of cases<\/span><\/td>\n<td>Ocrelizumab approved since 2018<\/td>\n<\/tr>\n<tr>\n<td><strong>Progressive-relapsing MS<\/strong><\/td>\n<td>Continuous progression with superimposed relapses<\/td>\n<td><span class=\"badge badge-teal\">Rare<\/span><\/td>\n<td>Combined approach<\/td>\n<\/tr>\n<tr>\n<td><strong>Clinically isolated syndrome (CIS)<\/strong><\/td>\n<td>First neurological episode, not yet established MS<\/td>\n<td><span class=\"badge badge-blue\">Possible precursor<\/span><\/td>\n<td>Monitoring and early treatment discussed<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<div class=\"warning-box\">\n    <pee>\u26a0\ufe0f <strong>Benign MS: a concept to nuance.<\/strong> For a long time, &#8220;benign MS&#8221; was used to describe forms with few relapses and little disability over 10-15 years. This concept is now being questioned: long-term follow-up studies show that even seemingly benign forms can evolve into progressive disability, and that cognitive disorders may be present while mobility is intact.<\/pee>\n<\/div>\n<p><!-- \u2500\u2500 SECTION 4 \u2500\u2500 --><\/p>\n<h2>4. Symptoms of multiple sclerosis<\/h2>\n<pee>MS is often called &#8220;the disease with a thousand faces&#8221; as its symptoms are varied, unpredictable, and different from one person to another. They depend on the location of the plaques in the brain and spinal cord. Some are visible from the outside, while others \u2014 the &#8220;invisible symptoms&#8221; \u2014 are often unknown or misunderstood by those around.<\/pee>\n<h3>4.1 Motor symptoms<\/h3>\n<pee>Motor disorders are among the most visible manifestations of MS. They include <strong>weakness or paralysis<\/strong> of one or more limbs (hemiparesis, paraparesis), balance and coordination disorders (ataxia), spasms, and muscle spasticity, as well as intention tremors. These symptoms directly affect mobility, walking, and daily activities.<\/pee>\n<h3>4.2 Sensory disorders<\/h3>\n<pee>Tingling, numbness, burning sensations or tightness, neuropathic pain are part of the frequent sensory symptoms in MS. Lhermitte&#8217;s sign \u2014 a sensation of electricity descending the spine when bending the neck \u2014 is characteristic of MS, even though it is not specific.<\/pee>\n<h3>4.3 Visual disorders<\/h3>\n<pee>Optic neuritis \u2014 inflammation of the optic nerve \u2014 is often the first sign of MS. It manifests as a decrease in unilateral visual acuity, pain with eye movement, and alteration of color vision. In most cases, recovery is good, but some sequelae may persist. Diplopia (double vision) due to involvement of the eye muscles is also common.<\/pee>\n<div class=\"cards-grid\">\n<div class=\"card\">\n<div class=\"card-icon blue\">\ud83d\ude34<\/div>\n<h4>Fatigue \u2014 the invisible symptom #1<\/h4>\n<pee>MS fatigue is unique: profound, overwhelming, not correlated with effort, it can occur suddenly even after a night of sleep. It affects 80% of patients and is often the most disabling symptom in daily life, yet little visible from the outside.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon teal\">\ud83e\udde0<\/div>\n<h4>Cognitive disorders<\/h4>\n<pee>50 to 70% of MS patients experience cognitive disorders: slowing of information processing, difficulties with episodic and working memory, concentration issues, and executive function problems. These symptoms are often poorly recognized but have a significant impact on professional and social life.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon yellow\">\ud83c\udf21\ufe0f<\/div>\n<h4>Uhthoff&#8217;s phenomenon<\/h4>\n<pee>The temporary worsening of symptoms in heat (hot bath, fever, intense exercise) is characteristic of MS. It is due to the increased sensitivity of demyelinated fibers to heat. This phenomenon is not a relapse \u2014 symptoms regress with cooling.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon pink\">\ud83d\udebd<\/div>\n<h4>Bladder and sphincter disorders<\/h4>\n<pee>Urinary urgency, incontinence, difficulties urinating, constipation \u2014 bladder and sphincter disorders affect 70 to 80% of patients at some point in their illness. They have a major impact on quality of life and are often addressed late due to embarrassment.<\/pee>\n    <\/div>\n<\/p><\/div>\n<div class=\"cta-outil\">\n<div class=\"cta-icon\">\ud83c\udf21\ufe0f<\/div>\n<div>\n<h4>DYNSEO Emotion Thermometer<\/h4>\n<pee>MS is often accompanied by emotional fluctuations that are difficult to verbalize. The emotion thermometer allows patients and caregivers to identify and communicate the emotional state of the day, thus facilitating mutual understanding and therapeutic follow-up.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/our-tools\/emotion-thermometer\/\" class=\"btn-blue\">Discover the tool<\/a>\n    <\/div>\n<\/p><\/div>\n<h3>4.4 Psychological and emotional symptoms<\/h3>\n<pee>MS does not only affect the body. Mood disorders \u2014 depression, anxiety, emotional lability \u2014 are common and multifactorial: they can result directly from brain lesions in the areas of emotional regulation, from the psychological reaction to a chronic disabling illness, or from the side effects of certain treatments.<\/pee>\n<pee>Depression affects about 50% of MS patients during their lifetime \u2014 a rate significantly higher than that observed in other comparable chronic diseases. It must be systematically screened and treated, as it significantly worsens quality of life and can impact adherence to treatments.<\/pee>\n<p>  <!-- \u2500\u2500 SECTION 5 \u2500\u2500 --><\/p>\n<h2>5. What is an MS relapse?<\/h2>\n<pee>In relapsing-remitting MS, the disease progresses through <strong>relapses<\/strong> \u2014 episodes of onset or worsening of neurological symptoms. Understanding what a relapse is, how to recognize it, and how to react is essential for patients and their loved ones.<\/pee>\n<div class=\"numbered-card\">\n<div class=\"num-badge\">\ud83d\udccb<\/div>\n<div class=\"num-content\">\n<h4>Definition of a relapse<\/h4>\n<pee>A relapse is defined as the onset or worsening of neurological symptoms lasting at least 24 hours, in the absence of fever or infection, separated by at least 30 days from the previous relapse. It corresponds to new active inflammation in the central nervous system.<\/pee>\n    <\/div>\n<\/p><\/div>\n<div class=\"numbered-card\">\n<div class=\"num-badge\">\u23f1\ufe0f<\/div>\n<div class=\"num-content\">\n<h4>Duration and recovery<\/h4>\n<pee>A relapse generally lasts from a few days to a few weeks. Recovery is often good, especially in the early years of the disease, but can be partial. Each relapse can leave varying sequelae \u2014 this is why early treatment of severe relapses is important.<\/pee>\n    <\/div>\n<\/p><\/div>\n<div class=\"numbered-card\">\n<div class=\"num-badge\">\ud83d\udea8<\/div>\n<div class=\"num-content\">\n<h4>Treatment of relapses<\/h4>\n<pee>Severe relapses are treated with high-dose corticosteroid infusions (methylprednisolone), which accelerate recovery without altering the long-term prognosis. This treatment should only be used for truly disabling relapses.<\/pee>\n    <\/div>\n<\/p><\/div>\n<p>  <!-- \u2500\u2500 SECTION 6 \u2500\u2500 --><\/p>\n<h2>6. The diagnosis of multiple sclerosis<\/h2>\n<pee>The diagnosis of MS is a pivotal moment in a person&#8217;s life. It currently relies on the <strong>McDonald criteria 2017<\/strong>, which integrate clinical, MRI, and biological data to make the diagnosis with maximum precision and minimum delay.<\/pee>\n<h3>6.1 MRI: the key examination<\/h3>\n<pee>Cerebral and spinal MRI is the reference examination in MS. It allows visualization of demyelination plaques, localization, dating (active lesions enhance after gadolinium injection), and monitoring their evolution. A brain with &#8220;black hole&#8221; lesions (old plaques) and recent lesions indicates active disease.<\/pee>\n<h3>6.2 Lumbar puncture and evoked potentials<\/h3>\n<pee>The lumbar puncture, which analyzes cerebrospinal fluid (CSF), can reveal oligoclonal bands of IgG \u2014 present in 85-90% of MS cases \u2014 and other inflammatory markers. Visual, auditory, or sensory evoked potentials measure nerve conduction speed and can detect clinically silent lesions.<\/pee>\n<div class=\"cta-formation\">\n<div class=\"cta-icon\">\ud83c\udf93<\/div>\n<div>\n<h4>Training \u2014 Understanding MS: essential guide for relatives<\/h4>\n<pee>An accessible and supportive training to help relatives understand the disease, its mechanisms, symptoms, and evolution \u2014 to better support without exhausting themselves.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/courses\/understanding-multiple-sclerosis-essential-guide-for-relatives-en\/\" class=\"btn-white\">Access the training \u2192<\/a>\n    <\/div>\n<\/p><\/div>\n<p>  <!-- \u2500\u2500 SECTION 7 \u2500\u2500 --><\/p>\n<h2>7. Treatments for multiple sclerosis in 2026<\/h2>\n<pee>The therapeutic management of MS has significantly progressed since the 1990s. Today, a wide arsenal of medications allows for reducing the frequency of relapses, slowing progression, and preventing lesions. However, there is still no curative treatment.<\/pee>\n<h3>7.1 Disease-modifying treatments (DMT)<\/h3>\n<pee>Disease-Modifying Therapies (DMT) aim to reduce inflammatory activity and prevent new relapses. They are divided into three levels of efficacy:<\/pee>\n<div class=\"table-wrap\">\n<table>\n<thead>\n<tr>\n<th>Level<\/th>\n<th>Main molecules<\/th>\n<th>Effectiveness on outbreaks<\/th>\n<th>Administration<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>1st line (moderate)<\/strong><\/td>\n<td>Beta interferon, Glatiramer acetate, Dimethyl fumarate, Teriflunomide<\/td>\n<td><span class=\"badge badge-yellow\">-30 to -50 %<\/span><\/td>\n<td>Injectable or oral<\/td>\n<\/tr>\n<tr>\n<td><strong>2nd line (high effectiveness)<\/strong><\/td>\n<td>Natalizumab, Fingolimod, Siponimod, Ozanimod<\/td>\n<td><span class=\"badge badge-blue\">-60 to -70 %<\/span><\/td>\n<td>Injectable or oral<\/td>\n<\/tr>\n<tr>\n<td><strong>3rd line (very high effectiveness)<\/strong><\/td>\n<td>Alemtuzumab, Ocrelizumab, Ofatumumab, Cladribine<\/td>\n<td><span class=\"badge badge-pink\">-70 to -90 %<\/span><\/td>\n<td>Infusion or oral<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<h3>7.2 Rehabilitation and non-drug management<\/h3>\n<pee>Rehabilitation plays a central role in the management of MS. Physiotherapy, occupational therapy, speech therapy (for swallowing or speech disorders), neuropsychology, psychology \u2014 each specialty contributes to maintaining functional abilities and quality of life. Adapted physical activity, long discouraged for fear of worsening symptoms, is now recognized as beneficial at all stages of the disease.<\/pee>\n<div class=\"cta-outil\">\n<div class=\"cta-icon\">\ud83d\udccb<\/div>\n<div>\n<h4>DYNSEO session follow-up sheet<\/h4>\n<pee>The session follow-up sheet allows healthcare professionals (physiotherapist, occupational therapist, psychomotor therapist) to track the exercises performed, the progress observed, and the goals for the next session \u2014 a valuable continuity tool in the follow-up of MS patients.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/nos-outils\/fiche-suivi-seance\/\" class=\"btn-blue\">Download the sheet<\/a>\n    <\/div>\n<\/p><\/div>\n<p>  <!-- \u2500\u2500 SECTION 8 \u2500\u2500 --><\/p>\n<h2>8. Cognitive disorders in MS: the hidden side of the disease<\/h2>\n<pee>Cognitive disorders are one of the most poorly recognized and least well-managed manifestations of MS. Yet, they affect more than half of patients and have a considerable impact on professional, family, and social life.<\/pee>\n<h3>8.1 What cognitive disorders in MS?<\/h3>\n<div class=\"profil-grid\">\n<div class=\"profil-card\">\n      <span class=\"emoji\">\u26a1<\/span><\/p>\n<h4>Cognitive slowing<\/h4>\n<pee>Slower information processing. Complex tasks take longer, even if performed correctly.<\/pee>\n    <\/div>\n<div class=\"profil-card\">\n      <span class=\"emoji\">\ud83d\udcbe<\/span><\/p>\n<h4>Episodic memory<\/h4>\n<pee>Difficulties in memorizing new information and retrieving it later. Procedural memory is often better preserved.<\/pee>\n    <\/div>\n<div class=\"profil-card\">\n      <span class=\"emoji\">\ud83c\udfaf<\/span><\/p>\n<h4>Sustained attention<\/h4>\n<pee>Difficulties in maintaining concentration on a long task, filtering out distractors, doing two things at once.<\/pee>\n    <\/div>\n<div class=\"profil-card\">\n      <span class=\"emoji\">\ud83d\uddc2\ufe0f<\/span><\/p>\n<h4>Executive functions<\/h4>\n<pee>Planning, organization, mental flexibility, and decision-making difficulties under time pressure.<\/pee>\n    <\/div>\n<\/p><\/div>\n<h3>8.2 Cognitive stimulation: an essential lever<\/h3>\n<pee>Regular cognitive stimulation is now recognized as a lever for maintaining intellectual capacities in MS. It does not heal existing lesions, but it promotes brain plasticity \u2014 the brain&#8217;s ability to create new compensatory circuits \u2014 and can slow cognitive decline.<\/pee>\n<pee>The <strong><a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\" style=\"color: var(--blue);\">CLINT<\/a><\/strong> app from DYNSEO is specially designed for adults with cognitive disorders, particularly in the context of neurological pathologies like MS. Its activities \u2014 memory, attention, language, logic \u2014 are adapted in difficulty, progressive, and accessible even for individuals experiencing significant cognitive fatigue.<\/pee>\n<div class=\"cta-outil\">\n<div class=\"cta-icon\">\ud83d\udcca<\/div>\n<div>\n<h4>DYNSEO Motivation Chart<\/h4>\n<pee>Maintaining regularity in cognitive stimulation can be difficult with fatigue related to MS. The motivation chart helps visualize goals, celebrate progress, and maintain engagement in cognitive activities on a daily basis.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/our-tools\/motivation-chart-dynseo-training-tool\/\" class=\"btn-blue\">Access the chart<\/a>\n    <\/div>\n<\/p><\/div>\n<div class=\"cta-formation\">\n<div class=\"cta-icon\">\ud83c\udf93<\/div>\n<div>\n<h4>Training \u2014 Fatigue and cognitive disorders in MS<\/h4>\n<pee>Understanding the mechanisms of fatigue and cognitive disorders in MS, identifying compensatory strategies and suitable stimulation tools \u2014 for patients as well as for relatives and caregivers.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/courses\/fatigue-and-cognitive-disorders-in-ms-what-families-can-do-en\/\" class=\"btn-white\">Discover the training \u2192<\/a>\n    <\/div>\n<\/p><\/div>\n<p>  <!-- \u2500\u2500 SECTION 9 \u2500\u2500 --><\/p>\n<h2>9. Living with MS: daily life, work, and relationships<\/h2>\n<pee>MS is a disease that settles into daily life. It disrupts projects, relationships, and professional and personal identity. Understanding these dimensions is essential to provide comprehensive and humane support.<\/pee>\n<h3>9.1 MS and professional life<\/h3>\n<pee>MS primarily affects young adults in full professional activity. Fatigue, cognitive disorders, unpredictable flare-ups, frequent medical appointments \u2014 maintaining professional activity often constitutes a major challenge. Yet, working remains possible and desirable for the vast majority of patients, especially with suitable accommodations.<\/pee>\n<div class=\"two-cols\">\n<div class=\"col-block\">\n<h4>\ud83c\udfe2 Workplace accommodations<\/h4>\n<ul>\n<li>Partial or total telecommuting<\/li>\n<li>Adjusted hours (morning fatigue or nap)<\/li>\n<li>Adapted position (ergonomic desk, chair)<\/li>\n<li>Disability recognition for access to AGEFIPH aids<\/li>\n<li>Therapeutic part-time work if necessary<\/li>\n<li>Cognitive assistance software<\/li>\n<\/ul><\/div>\n<div class=\"col-block\">\n<h4>\ud83d\udcac To tell or not to tell the employer?<\/h4>\n<ul>\n<li>No legal obligation to disclose MS<\/li>\n<li>The occupational physician, medical confidentiality guaranteed<\/li>\n<li>Disability recognition possible without revealing the diagnosis<\/li>\n<li>MS France Association: legal advice<\/li>\n<li>Cap Emploi: tailored professional support<\/li>\n<li>Each situation is unique \u2014 personal decision<\/li>\n<\/ul><\/div>\n<\/p><\/div>\n<h3>9.2 MS, couple and surroundings<\/h3>\n<pee>MS affects the surroundings as much as the patient. Loved ones \u2014 especially the partner \u2014 may find themselves in an unchosen caregiver role, with the risks of burnout that this entails. Communication within the couple transforms, sometimes leading to a rupture of the intimate balance.<\/pee>\n<pee>Expressing what one feels, naming the invisible fatigue, discussing fears and mutual expectations without waiting for a crisis \u2014 this is the challenge that many couples facing MS take on. Psychological support for both members of the couple is often valuable.<\/pee>\n<div class=\"cta-outil\">\n<div class=\"cta-icon\">\ud83d\udcca<\/div>\n<div>\n<h4>3-column table \u2014 structuring thoughts and emotions<\/h4>\n<pee>The 3-column table from DYNSEO is a tool for cognitive and emotional structuring. It helps organize thoughts, identify obstacles and solutions \u2014 particularly useful for MS patients facing planning and prioritization difficulties.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/our-tools\/3-column-table\/\" class=\"btn-blue\">Use the tool<\/a>\n    <\/div>\n<\/p><\/div>\n<div class=\"cta-formation\">\n<div class=\"cta-icon\">\ud83c\udf93<\/div>\n<div>\n<h4>Training \u2014 Living with long-term MS: caregiver, couple, and future<\/h4>\n<pee>A training designed for caregivers and couples: understanding the impact of MS on relational dynamics, preventing caregiver burnout, and building a shared life project despite the disease.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/courses\/living-with-long-term-ms-caregiver-couple-and-future-en\/\" class=\"btn-white\">Access the training \u2192<\/a>\n    <\/div>\n<\/p><\/div>\n<p>  <!-- \u2500\u2500 SECTION 10 \u2500\u2500 --><\/p>\n<h2>10. MS in institutions: supporting advanced forms<\/h2>\n<pee>In the progressive or advanced forms of MS, some patients are cared for in medico-social establishments (Nursing home, MAS, FAM) or benefit from intensive home care. Support in these contexts requires specific training for healthcare professionals.<\/pee>\n<pee>Healthcare providers facing MS in institutions must understand the particularities of the disease: the variability of symptoms from day to day, the impact of heat on capacities, the cognitive fatigue that is not always visible, the often underestimated bladder and sphincter disorders, and the central psychological dimension of support.<\/pee>\n<div class=\"cta-formation\">\n<div class=\"cta-icon\">\ud83c\udf93<\/div>\n<div>\n<h4>Training \u2014 MS in institutions: understanding and adapting practice<\/h4>\n<pee>A training dedicated to healthcare professionals who support MS patients in institutions: understanding the specifics of the disease, adapting care, preventing complications, and maintaining autonomy as long as possible.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/courses\/multiple-sclerosis-in-an-institution-understanding-the-disease-and-adapting-professional-practice-en\/\" class=\"btn-white\">Discover the training \u2192<\/a>\n    <\/div>\n<\/p><\/div>\n<p>  <!-- \u2500\u2500 SECTION 11 \u2500\u2500 --><\/p>\n<h2>11. Maintaining autonomy: strategies and practical tools<\/h2>\n<pee>Preserving autonomy is a central objective in supporting MS. This involves home adaptations, the use of technical aids, regular cognitive stimulation, and psychological support. But it also involves therapeutic education for the patient that allows them to understand their disease, recognize warning signs, and adapt their lifestyle.<\/pee>\n<h3>11.1 Adapting the home and daily life<\/h3>\n<div class=\"checklist\">\n<li>Grab bars in the bathroom and stairs to prevent falls<\/li>\n<li>Shower seat and flexible showerhead to manage fatigue and balance<\/li>\n<li>Organization of the kitchen with suitable utensils and accessible work surface<\/li>\n<li>Sufficient lighting to compensate for any visual disorders<\/li>\n<li>Fan or air conditioner to avoid overheating (Uhthoff phenomenon)<\/li>\n<li>Reminder and organization applications to compensate for memory disorders<\/li>\n<li>Visual schedule displayed to structure days and reduce cognitive load<\/li>\n<li>Electric scooter or wheelchair for mobility in case of significant fatigue<\/li><\/div>\n<h3>11.2 Cognitive stimulation in daily life<\/h3>\n<pee>Regular cognitive exercises \u2014 reading, puzzles, strategy games, manual activities \u2014 help maintain brain plasticity and preserve intellectual abilities in MS. Digital stimulation programs like the <strong><a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\" style=\"color: var(--blue);\">CLINT<\/a><\/strong> app from DYNSEO offer structured, progressive, and accessible stimulation even on days of significant fatigue.<\/pee>\n<pee>DYNSEO also offers a complete suite of <strong><a href=\"https:\/\/www.dynseo.com\/en\/our-tests\/\" style=\"color: var(--blue);\">online cognitive tests<\/a><\/strong> that allow for regular assessment of cognitive functions \u2014 memory, attention, processing speed \u2014 and early detection of any potential changes. These tools, used in conjunction with neuropsychological monitoring, provide a valuable dashboard for both the patient and the care team.<\/pee>\n<div class=\"cta-formation\">\n<div class=\"cta-icon\">\ud83c\udf93<\/div>\n<div>\n<h4>Training \u2014 MS and daily life: maintaining autonomy<\/h4>\n<pee>All the practical strategies to adapt daily life to MS, prevent complications, manage fatigue, and maintain autonomy for as long as possible \u2014 for patients and caregivers.<\/pee>\n      <a href=\"https:\/\/www.dynseo.com\/en\/courses\/sep-and-daily-life-maintaining-autonomy-and-preventing-complications-en\/\" class=\"btn-white\">Access the training \u2192<\/a>\n    <\/div>\n<\/p><\/div>\n<p>  <!-- \u2500\u2500 SECTION 12 \u2500\u2500 --><\/p>\n<h2>12. Research on MS in 2026: concrete hopes<\/h2>\n<pee>MS is one of the neurological diseases where research is progressing the fastest. In 2026, several research avenues open up truly promising perspectives for patients.<\/pee>\n<h3>12.1 Remyelination therapies<\/h3>\n<pee>So far, available treatments mainly act on inflammation to prevent new lesions. But they do not allow for the repair of already destroyed myelin. Remyelination therapies \u2014 which aim to stimulate precursor cells of oligodendrocytes to rebuild the damaged myelin sheath \u2014 represent the next great hope. Several molecules are in advanced clinical trials.<\/pee>\n<h3>12.2 Neuroprotection<\/h3>\n<pee>Alongside remyelination, neuroprotective therapies seek to preserve axons from damage caused by chronic inflammation. The progression of disability in progressive forms is largely related to irreversible axonal loss \u2014 this is the aspect that neuroprotective therapies aim to prevent.<\/pee>\n<h3>12.3 The role of the microbiome and new therapeutic targets<\/h3>\n<pee>The growing understanding of the role of the gut microbiome in MS paves the way for unprecedented therapeutic approaches: targeted probiotics, anti-inflammatory diets, and even fecal microbiota transplantation in research contexts. These experimental avenues illustrate the paradigm shift towards a more systemic view of the disease.<\/pee>\n<div class=\"tip-box\">\n<div class=\"icon\">\ud83d\udd2c<\/div>\n<pee><strong>The EBV-MS link:<\/strong> The very strong demonstration of the link between Epstein-Barr virus infection and the subsequent development of MS has rekindled hopes for a preventive vaccine. If an anti-EBV vaccine proves effective in preventing mononucleosis, it could also reduce the incidence of MS \u2014 a prospect that mobilizes several global research teams.<\/pee>\n  <\/div>\n<p>  <!-- \u2500\u2500 SECTION 13 \u2500\u2500 --><\/p>\n<h2>13. Resources, associations, and support for MS patients<\/h2>\n<pee>Being diagnosed with MS means joining a community of patients, loved ones, and professionals committed to fighting the disease. Many resources exist to ensure you do not go through this ordeal alone.<\/pee>\n<h3>13.1 Leading associations in France<\/h3>\n<div class=\"cards-grid\">\n<div class=\"card\">\n<div class=\"card-icon blue\">\ud83c\udfdb\ufe0f<\/div>\n<h4>ARSEP<\/h4>\n<pee>The Foundation for Research Aid on MS funds research and publishes validated medical information. It organizes fundraising events and provides educational resources for patients and their families.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon teal\">\ud83e\udd1d<\/div>\n<h4>MS France (formerly LFSEP)<\/h4>\n<pee>The French League Against Multiple Sclerosis supports patients in their administrative and social processes, offers local support groups, and provides legal and professional assistance.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon yellow\">\ud83d\udc68\u200d\u2695\ufe0f<\/div>\n<h4>OFSEP<\/h4>\n<pee>The French Observatory of MS is a national cohort that follows thousands of patients over time. Participation in OFSEP contributes to research and allows patients to benefit from enhanced monitoring in expert centers.<\/pee>\n    <\/div>\n<div class=\"card\">\n<div class=\"card-icon pink\">\ud83d\udcf1<\/div>\n<h4>Monitoring Applications<\/h4>\n<pee>Dedicated applications allow patients to record their symptoms, fatigue levels, relapses, and treatments. This digital health journal is valuable during neurological consultations.<\/pee>\n    <\/div>\n<\/p><\/div>\n<h3>13.2 Patient Therapeutic Education (PTE)<\/h3>\n<pee>Patient therapeutic education is a recognized right for people with chronic diseases. For MS patients, PTE programs are offered in reference centers: they learn to understand their disease, manage fatigue, recognize relapses, adapt their lifestyle, and communicate with caregivers. These programs significantly improve treatment adherence and quality of life.<\/pee>\n<pee>DYNSEO&#8217;s online training complements these initiatives by providing flexible and accessible access to quality information, whether for the patients themselves, their relatives, or the healthcare professionals who support them. The training <strong><a href=\"https:\/\/www.dynseo.com\/en\/courses\/understanding-multiple-sclerosis-essential-guide-for-relatives-en\/\" style=\"color: var(--blue);\">Essential Guide for Relatives<\/a><\/strong> is particularly suitable for families looking to understand without getting lost in medical jargon.<\/pee>\n<div class=\"quote-box\">\n    <pee>\u00ab Understanding MS is not resigning oneself to the disease. It is giving oneself the means to live with it differently \u2014 with more serenity, more anticipation, and more humanity in the caregiver-patient relationship. \u00bb<\/pee>\n    <cite>\u2014 Perspective of multidisciplinary teams in neurology<\/cite>\n  <\/div>\n<h3>13.3 Nutrition, lifestyle, and psychological support<\/h3>\n<pee>If no diet has been scientifically proven as a treatment for MS, several data converge on the importance of an anti-inflammatory diet. The Mediterranean diet \u2014 rich in vegetables, fruits, fatty fish, olive oil, and legumes \u2014 is associated with better neurological health. Vitamin D supplementation is widely recommended for MS patients in consultation with the neurologist, as many patients have documented deficiencies. Stress management, quality sleep, and adapted physical activity are the other pillars of a favorable lifestyle.<\/pee>\n<pee>Psychological support is an essential component of the overall management of MS, not a luxury. Living with an unpredictable chronic illness generates a real psychological burden: mourning for the life before, fear of the future, uncertainty about the progression, questioning one&#8217;s professional and personal identity. Neuropsychologists play a particularly important role in supporting cognitive disorders related to MS: they precisely assess the cognitive profile, propose suitable compensation strategies, and assist the patient in managing their daily difficulties. In parallel, the regular use of cognitive stimulation tools like the <strong><a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\" style=\"color: var(--blue);\">CLINT<\/a><\/strong> app from DYNSEO helps maintain structured cognitive activity between professional follow-up sessions.<\/pee>\n<pee>Finally, the online cognitive tests offered by DYNSEO on the <strong><a href=\"https:\/\/www.dynseo.com\/en\/our-tests\/\" style=\"color: var(--blue);\">our-tests<\/a><\/strong> page are a valuable monitoring tool: they allow the patient and their care team to track the evolution of cognitive functions over time, to detect any deterioration early, and to adjust stimulation programs accordingly. This proactive approach, combining medical follow-up and self-management, is at the heart of the new way to support MS in 2026.<\/pee>\n<div class=\"highlight-box\">\n<h4>\ud83c\udf1f The essential message for patients and their loved ones<\/h4>\n<pee>MS is a serious disease that deserves serious care. But it does not define a person in their entirety. Tens of thousands of people with MS lead active professional lives, fulfilling relationships, family projects, and rich community engagements. The secret: to inform oneself without drowning, to surround oneself without isolating, to care for oneself without reducing oneself to their illness. DYNSEO supports this approach with accessible training, practical tools, and a caring philosophy: every person deserves to be supported with the right tools, at the right time, at their own pace.<\/pee>\n<\/div>\n<pee>It is important to emphasize that MS affects people in the prime of their lives, often in the midst of building their life \u2014 professional, family, personal. This context makes psychological, social, and practical support even more crucial. Loved ones, caregivers, and employers have a decisive role to play so that people with MS can continue to thrive, contribute, and envision the future. Informing, training, equipping, and supporting: this is the mission that DYNSEO pursues through its training, free tools, and cognitive stimulation applications, in service of patients and all those around them. Understanding of MS progresses each year, and with it, hopes for increasingly effective treatments to preserve quality of life and slow down disability. Staying informed, active, and surrounded remains the best strategy against this complex but increasingly manageable disease.<\/pee>\n<!-- \u2500\u2500 CONCLUSION \u2500\u2500 --><\/p>\n<div class=\"conclusion\">\n<h2>What to remember about MS<\/h2>\n<pee>Multiple sclerosis is a complex, unpredictable disease, but it is increasingly well understood and treated. Early diagnosis, multidisciplinary care, and an adapted life allow the vast majority of patients to maintain their quality of life for a long time. MS is not a life on hold \u2014 it is a reinvented life, with the right tools and the right supporters by its side.<\/pee>\n    <a href=\"https:\/\/www.dynseo.com\/en\/courses\/understanding-multiple-sclerosis-essential-guide-for-relatives-en\/\" class=\"btn-cta\">Explore DYNSEO&#8217;s MS training \u2192<\/a>\n<\/div>\n<p><\/main><\/p>\n<p><!-- \u2550\u2550 FAQ \u2550\u2550 --><\/p>\n<section class=\"faq-section\">\n<div class=\"container\">\n<h2>FAQ \u2014 Frequently Asked Questions about Multiple Sclerosis<\/h2>\n<div class=\"faq-item\">\n<h4><span>Q1<\/span> Is multiple sclerosis fatal?<\/h4>\n<pee>MS only slightly reduces life expectancy in the vast majority of cases \u2014 by 5 to 10 years according to the most recent studies, a gap that tends to narrow thanks to modern treatments. It is not a fatal disease in the short term. However, very severe forms and complications (recurrent urinary infections, pneumonia related to swallowing disorders) can be serious. MS can also lead to significant disability, which justifies early and active management.<\/pee>\n    <\/div>\n<div class=\"faq-item\">\n<h4><span>Q2<\/span> Can you get pregnant when you have MS?<\/h4>\n<pee>Yes, and pregnancy even has a protective effect on MS: relapses are less frequent during pregnancy, especially in the third trimester. However, the risk of relapse increases in the 3-6 months after childbirth. A pregnancy in a woman with MS should be planned and discussed with the neurologist, particularly to adjust the baseline treatment before conception and after childbirth. MS does not prevent becoming a mother.<\/pee>\n    <\/div>\n<div class=\"faq-item\">\n<h4><span>Q3<\/span> What is the difference between a relapse and a pseudo-relapse?<\/h4>\n<pee>A pseudo-relapse (or false relapse) is a temporary worsening of already existing symptoms, without new active inflammatory lesions. It is often triggered by heat (Uhthoff&#8217;s phenomenon), an infection, a feverish state, or great fatigue. A true relapse involves new symptoms or a clear worsening of old symptoms, lasting more than 24 hours, without fever. The distinction is important because true relapses may require treatment with corticosteroids, while pseudo-relapses do not.<\/pee>\n    <\/div>\n<div class=\"faq-item\">\n<h4><span>Q4<\/span> Can you engage in sports activities with MS?<\/h4>\n<pee>Not only is it possible, but it is highly recommended. Regular and adapted physical activity improves fatigue, muscle strength, balance, sleep quality, mood, and even cognitive functions in MS. Swimming (in cool water), yoga, Pilates, indoor cycling, and Nordic walking are particularly well-suited. Intense efforts that significantly raise body temperature should be avoided. An adapted physical activity program (APA) with a professional is ideal.<\/pee>\n    <\/div>\n<div class=\"faq-item\">\n<h4><span>Q5<\/span> How to help a loved one with MS without exhausting yourself?<\/h4>\n<pee>Helping a loved one with MS is a valuable but demanding commitment. To avoid burnout, it is essential to accept external help (home services, caregiver relief), maintain personal spaces and activities for oneself, participate in support groups for caregivers, and educate oneself to better understand the disease. DYNSEO offers training dedicated to caregivers and couples: <a href=\"https:\/\/www.dynseo.com\/en\/courses\/living-with-long-term-ms-caregiver-couple-and-future-en\/\" style=\"color: var(--blue);\">Living with MS in the long term<\/a>. Taking care of oneself is not abandoning the other \u2014 it is the condition for being able to continue supporting them.<\/pee>\n    <\/div>\n<\/p><\/div>\n<\/section>\n<p><!-- \u2550\u2550 FOOTER \u2550\u2550 --><\/p>\n<footer class=\"article-footer\">\n  <pee>Discover all DYNSEO resources to support neurological diseases<\/pee>\n<div class=\"footer-links\">\n    <a href=\"https:\/\/www.dynseo.com\/en\/our-training-courses\/\">Our MS training<\/a><br \/>\n    <a href=\"https:\/\/www.dynseo.com\/en\/our-tools\/\">Free tools<\/a><br \/>\n    <a href=\"https:\/\/www.dynseo.com\/en\/our-tests\/\">Cognitive tests<\/a><br \/>\n    <a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\">CLINT App<\/a><br \/>\n    <a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/scarlett-brain-games-for-seniors\/\">SCARLETT App<\/a>\n  <\/div>\n<\/footer>\n<\/div>\n<p>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":100456,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section fb_built=\"1\" admin_label=\"Article HTML\" _builder_version=\"4.16\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_row admin_label=\"Contenu\" _builder_version=\"4.16\" width=\"100%\" max_width=\"100%\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.16\" global_colors_info=\"{}\"][et_pb_code admin_label=\"HTML import\u00e9\" _builder_version=\"4.16\" global_colors_info=\"{}\"]<style type=\"text\/css\">\n:root {\n    --blue: #5e5ed7;\n    --blue-dark: #5268c9;\n    --teal: #a9e2e4;\n    --yellow: #ffeca7;\n    --pink: #e73469;\n    --white: #ffffff;\n    --light-bg: #f8f9ff;\n    --text: #2d2d4e;\n    --text-light: #6b6b8a;\n    --border-radius: 16px;\n    --shadow: 0 4px 24px rgba(94,94,215,0.10);\n    --shadow-card: 0 2px 16px rgba(94,94,215,0.08);\n  }\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Montserrat:wght@400;500;600;700;800&family=Poppins:wght@300;400;500;600&display=swap');\n\n  \n\n  * { box-sizing: border-box; margin: 0; padding: 0; }\n.dbi-art-b0224d { font-family: 'Poppins', sans-serif; color: var(--text); background: #fff; line-height: 1.75; font-size: 16px; }\n.dbi-art-b0224d h1, .dbi-art-b0224d h2, .dbi-art-b0224d h3, .dbi-art-b0224d h4 { font-family: 'Montserrat', sans-serif; }\n.dbi-art-b0224d .hero {\n    background: linear-gradient(135deg, var(--blue) 0%, var(--blue-dark) 60%, #3d4fa8 100%);\n    color: white; padding: 72px 24px 56px; text-align: center; position: relative; overflow: hidden;\n  }\n.dbi-art-b0224d .hero::before {\n    content: ''; position: absolute; inset: 0;\n    background: url(\"data:image\/svg+xml,%3Csvg width='60' height='60' viewBox='0 0 60 60' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cg fill='none' fill-rule='evenodd'%3E%3Cg fill='%23ffffff' fill-opacity='0.04'%3E%3Ccircle cx='30' cy='30' r='20'\/%3E%3C\/g%3E%3C\/g%3E%3C\/svg%3E\");\n    pointer-events: none;\n  }\n.dbi-art-b0224d .hero-tag { display: inline-block; background: rgba(255,255,255,0.18); border: 1px solid rgba(255,255,255,0.3); color: white; padding: 6px 18px; border-radius: 50px; font-size: 13px; font-weight: 600; letter-spacing: 1px; text-transform: uppercase; margin-bottom: 20px; }\n.dbi-art-b0224d .hero h1 { font-size: clamp(26px, 4vw, 44px); font-weight: 800; line-height: 1.2; max-width: 820px; margin: 0 auto 20px; }\n.dbi-art-b0224d .hero-sub { font-size: 17px; opacity: 0.88; max-width: 620px; margin: 0 auto 32px; font-weight: 300; }\n.dbi-art-b0224d .hero-meta { display: flex; justify-content: center; gap: 24px; flex-wrap: wrap; font-size: 13px; opacity: 0.75; }\n.dbi-art-b0224d .hero-meta span { display: flex; align-items: center; gap: 6px; }\n.dbi-art-b0224d .container { max-width: 860px; margin: 0 auto; padding: 0 24px; }\n.dbi-art-b0224d .section { padding: 52px 0 40px; }\n.dbi-art-b0224d .stats-bar { background: var(--light-bg); border-bottom: 1px solid rgba(94,94,215,0.08); padding: 32px 24px; }\n.dbi-art-b0224d .stats-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(160px, 1fr)); gap: 16px; max-width: 860px; margin: 0 auto; }\n.dbi-art-b0224d .stat-item { text-align: center; padding: 20px 12px; background: white; border-radius: var(--border-radius); box-shadow: var(--shadow-card); }\n.dbi-art-b0224d .stat-num { font-family: 'Montserrat', sans-serif; font-size: 30px; font-weight: 800; color: var(--blue); display: block; }\n.dbi-art-b0224d .stat-label { font-size: 12px; color: var(--text-light); font-weight: 500; margin-top: 4px; display: block; }\n.dbi-art-b0224d .intro-block { border-left: 4px solid var(--blue); background: rgba(94,94,215,0.04); padding: 24px 28px; border-radius: 0 var(--border-radius) var(--border-radius) 0; margin: 36px 0; }\n.dbi-art-b0224d .intro-block p { font-size: 17px; line-height: 1.8; color: var(--text); }\n.dbi-art-b0224d h2 { font-size: clamp(20px, 3vw, 28px); font-weight: 800; color: var(--blue); margin: 48px 0 20px; padding-bottom: 12px; border-bottom: 2px solid var(--teal); }\n.dbi-art-b0224d h3 { font-size: 18px; font-weight: 700; color: var(--blue-dark); margin: 32px 0 14px; }\n.dbi-art-b0224d p { margin-bottom: 18px; color: var(--text); }\n.dbi-art-b0224d .cards-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(240px, 1fr)); gap: 20px; margin: 28px 0; }\n.dbi-art-b0224d .card { background: white; border-radius: var(--border-radius); padding: 28px 24px; box-shadow: var(--shadow-card); border: 1px solid rgba(94,94,215,0.08); transition: transform 0.2s, box-shadow 0.2s; }\n.dbi-art-b0224d .card:hover { transform: translateY(-3px); box-shadow: var(--shadow); }\n.dbi-art-b0224d .card-icon { width: 48px; height: 48px; border-radius: 12px; display: flex; align-items: center; justify-content: center; font-size: 22px; margin-bottom: 16px; }\n.dbi-art-b0224d .card-icon.blue { background: rgba(94,94,215,0.1); }\n.dbi-art-b0224d .card-icon.teal { background: rgba(169,226,228,0.3); }\n.dbi-art-b0224d .card-icon.yellow { background: rgba(255,236,167,0.5); }\n.dbi-art-b0224d .card-icon.pink { background: rgba(231,52,105,0.1); }\n.dbi-art-b0224d .card h4 { font-size: 15px; font-weight: 700; color: var(--text); margin-bottom: 10px; font-family: 'Montserrat', sans-serif; }\n.dbi-art-b0224d .card p { font-size: 14px; color: var(--text-light); margin: 0; line-height: 1.65; }\n.dbi-art-b0224d .numbered-card { display: flex; gap: 20px; align-items: flex-start; background: white; border-radius: var(--border-radius); padding: 24px; box-shadow: var(--shadow-card); border: 1px solid rgba(94,94,215,0.07); margin-bottom: 16px; }\n.dbi-art-b0224d .num-badge { min-width: 44px; height: 44px; border-radius: 50%; background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; font-family: 'Montserrat', sans-serif; font-weight: 800; font-size: 17px; display: flex; align-items: center; justify-content: center; flex-shrink: 0; }\n.dbi-art-b0224d .num-content h4 { font-size: 15px; font-weight: 700; color: var(--text); margin-bottom: 8px; font-family: 'Montserrat', sans-serif; }\n.dbi-art-b0224d .num-content p { font-size: 14px; color: var(--text-light); margin: 0; }\n.dbi-art-b0224d .table-wrap { overflow-x: auto; margin: 28px 0; border-radius: var(--border-radius); box-shadow: var(--shadow-card); }\n.dbi-art-b0224d table { width: 100%; border-collapse: collapse; font-size: 14px; }\n.dbi-art-b0224d thead tr { background: linear-gradient(90deg, var(--blue), var(--blue-dark)); color: white; }\n.dbi-art-b0224d thead th { padding: 16px 18px; text-align: left; font-family: 'Montserrat', sans-serif; font-weight: 700; }\n.dbi-art-b0224d tbody tr:nth-child(even) { background: var(--light-bg); }\n.dbi-art-b0224d tbody tr:nth-child(odd) { background: white; }\n.dbi-art-b0224d tbody td { padding: 14px 18px; color: var(--text); border-bottom: 1px solid rgba(94,94,215,0.06); }\n.dbi-art-b0224d tbody tr:last-child td { border-bottom: none; }\n.dbi-art-b0224d .badge { display: inline-block; padding: 3px 10px; border-radius: 50px; font-size: 12px; font-weight: 600; }\n.dbi-art-b0224d .badge-blue { background: rgba(94,94,215,0.12); color: var(--blue); }\n.dbi-art-b0224d .badge-teal { background: rgba(169,226,228,0.4); color: #2a8a8c; }\n.dbi-art-b0224d .badge-yellow { background: rgba(255,236,167,0.8); color: #a87800; }\n.dbi-art-b0224d .badge-pink { background: rgba(231,52,105,0.1); color: var(--pink); }\n.dbi-art-b0224d .tip-box { background: var(--yellow); border-radius: var(--border-radius); padding: 22px 26px; margin: 28px 0; display: flex; gap: 16px; align-items: flex-start; }\n.dbi-art-b0224d .tip-box .icon { font-size: 22px; flex-shrink: 0; margin-top: 2px; }\n.dbi-art-b0224d .tip-box p { font-size: 15px; margin: 0; color: var(--text); }\n.dbi-art-b0224d .tip-box strong { color: var(--blue-dark); }\n.dbi-art-b0224d .warning-box { background: rgba(231,52,105,0.07); border-left: 4px solid var(--pink); border-radius: 0 var(--border-radius) var(--border-radius) 0; padding: 20px 24px; margin: 28px 0; }\n.dbi-art-b0224d .warning-box p { font-size: 15px; margin: 0; color: var(--text); }\n.dbi-art-b0224d .quote-box { background: rgba(94,94,215,0.06); border-left: 4px solid var(--blue); border-radius: 0 var(--border-radius) var(--border-radius) 0; padding: 22px 28px; margin: 28px 0; }\n.dbi-art-b0224d .quote-box p { font-size: 16px; font-style: italic; color: var(--text); margin: 0; }\n.dbi-art-b0224d .quote-box cite { display: block; margin-top: 10px; font-size: 13px; color: var(--text-light); font-style: normal; font-weight: 600; }\n.dbi-art-b0224d .checklist { background: white; border-radius: var(--border-radius); padding: 28px 32px; box-shadow: var(--shadow-card); margin: 28px 0; list-style: none; }\n.dbi-art-b0224d .checklist li { padding: 10px 0; border-bottom: 1px solid rgba(94,94,215,0.07); font-size: 15px; display: flex; gap: 12px; align-items: flex-start; }\n.dbi-art-b0224d .checklist li:last-child { border-bottom: none; }\n.dbi-art-b0224d .checklist li::before { content: '\u2714'; color: var(--blue); font-weight: 700; flex-shrink: 0; margin-top: 1px; }\n.dbi-art-b0224d .cta-formation { background: linear-gradient(135deg, var(--blue) 0%, var(--blue-dark) 100%); border-radius: var(--border-radius); padding: 36px 32px; margin: 36px 0; color: white; display: flex; gap: 24px; align-items: center; flex-wrap: wrap; }\n.dbi-art-b0224d .cta-formation .cta-icon { font-size: 40px; flex-shrink: 0; }\n.dbi-art-b0224d .cta-formation h4 { font-size: 18px; font-weight: 800; font-family: 'Montserrat', sans-serif; margin-bottom: 8px; color: white; }\n.dbi-art-b0224d .cta-formation p { font-size: 14px; opacity: 0.88; margin: 0 0 16px; color: white; }\n.dbi-art-b0224d .btn-white { display: inline-block; background: white; color: var(--blue); font-family: 'Montserrat', sans-serif; font-weight: 700; font-size: 14px; padding: 12px 26px; border-radius: 50px; text-decoration: none; transition: transform 0.2s, box-shadow 0.2s; }\n.dbi-art-b0224d .btn-white:hover { transform: translateY(-2px); box-shadow: 0 8px 20px rgba(0,0,0,0.15); }\n.dbi-art-b0224d .cta-outil { background: var(--teal); border-radius: var(--border-radius); padding: 28px 28px; margin: 28px 0; display: flex; gap: 20px; align-items: center; flex-wrap: wrap; }\n.dbi-art-b0224d .cta-outil .cta-icon { font-size: 36px; flex-shrink: 0; }\n.dbi-art-b0224d .cta-outil h4 { font-size: 16px; font-weight: 700; font-family: 'Montserrat', sans-serif; color: var(--text); margin-bottom: 6px; }\n.dbi-art-b0224d .cta-outil p { font-size: 14px; color: var(--text); margin: 0 0 14px; }\n.dbi-art-b0224d .btn-blue { display: inline-block; background: var(--blue); color: white; font-family: 'Montserrat', sans-serif; font-weight: 700; font-size: 13px; padding: 10px 22px; border-radius: 50px; text-decoration: none; transition: transform 0.2s; }\n.dbi-art-b0224d .btn-blue:hover { transform: translateY(-2px); }\n.dbi-art-b0224d .two-cols { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 28px 0; }\n@media (max-width: 600px) {\n.dbi-art-b0224d .two-cols { grid-template-columns: 1fr; }\n}\n.dbi-art-b0224d .col-block { background: white; border-radius: var(--border-radius); padding: 24px; box-shadow: var(--shadow-card); }\n.dbi-art-b0224d .col-block h4 { font-family: 'Montserrat', sans-serif; font-size: 15px; font-weight: 700; margin-bottom: 14px; display: flex; gap: 10px; align-items: center; }\n.dbi-art-b0224d .col-block ul { list-style: none; padding: 0; }\n.dbi-art-b0224d .col-block ul li { font-size: 14px; padding: 7px 0; border-bottom: 1px solid rgba(94,94,215,0.06); color: var(--text); padding-left: 18px; position: relative; }\n.dbi-art-b0224d .col-block ul li::before { content: '\u2192'; position: absolute; left: 0; color: var(--blue); font-weight: 700; }\n.dbi-art-b0224d .col-block ul li:last-child { border-bottom: none; }\n.dbi-art-b0224d .highlight-box { background: linear-gradient(135deg, rgba(169,226,228,0.3), rgba(255,236,167,0.3)); border-radius: var(--border-radius); padding: 28px; margin: 28px 0; border: 1px solid rgba(169,226,228,0.5); }\n.dbi-art-b0224d .highlight-box h4 { font-family: 'Montserrat', sans-serif; font-size: 16px; font-weight: 700; color: var(--blue); margin-bottom: 12px; }\n.dbi-art-b0224d .highlight-box p { font-size: 15px; margin: 0; }\n.dbi-art-b0224d .timeline { margin: 28px 0; position: relative; }\n.dbi-art-b0224d .timeline::before { content: ''; position: absolute; left: 24px; top: 0; bottom: 0; width: 3px; background: linear-gradient(180deg, var(--blue), var(--teal)); border-radius: 3px; }\n.dbi-art-b0224d .timeline-item { display: flex; gap: 20px; margin-bottom: 24px; position: relative; }\n.dbi-art-b0224d .timeline-dot { min-width: 48px; height: 48px; border-radius: 50%; background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; display: flex; align-items: center; justify-content: center; font-size: 18px; flex-shrink: 0; z-index: 1; box-shadow: 0 4px 12px rgba(94,94,215,0.3); }\n.dbi-art-b0224d .timeline-content { background: white; border-radius: var(--border-radius); padding: 20px 24px; box-shadow: var(--shadow-card); flex: 1; border: 1px solid rgba(94,94,215,0.07); }\n.dbi-art-b0224d .timeline-content h4 { font-family: 'Montserrat', sans-serif; font-size: 15px; font-weight: 700; color: var(--blue); margin-bottom: 8px; }\n.dbi-art-b0224d .timeline-content p { font-size: 14px; color: var(--text-light); margin: 0; }\n.dbi-art-b0224d .profil-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 16px; margin: 28px 0; }\n.dbi-art-b0224d .profil-card { background: white; border-radius: var(--border-radius); padding: 22px 18px; box-shadow: var(--shadow-card); text-align: center; border-top: 4px solid var(--blue); }\n.dbi-art-b0224d .profil-card .emoji { font-size: 32px; margin-bottom: 10px; display: block; }\n.dbi-art-b0224d .profil-card h4 { font-size: 14px; font-weight: 700; font-family: 'Montserrat', sans-serif; margin-bottom: 8px; color: var(--blue); }\n.dbi-art-b0224d .profil-card p { font-size: 13px; color: var(--text-light); margin: 0; line-height: 1.6; }\n.dbi-art-b0224d .faq-section { background: var(--light-bg); padding: 52px 24px; margin-top: 52px; }\n.dbi-art-b0224d .faq-section h2 { color: var(--blue); border-color: var(--teal); }\n.dbi-art-b0224d .faq-item { background: white; border-radius: var(--border-radius); padding: 24px 28px; margin-bottom: 14px; box-shadow: var(--shadow-card); }\n.dbi-art-b0224d .faq-item h4 { font-family: 'Montserrat', sans-serif; font-size: 16px; font-weight: 700; color: var(--blue); margin-bottom: 12px; display: flex; gap: 12px; align-items: flex-start; }\n.dbi-art-b0224d .faq-item h4 span { color: var(--teal); flex-shrink: 0; }\n.dbi-art-b0224d .faq-item p { font-size: 15px; margin: 0; color: var(--text); }\n.dbi-art-b0224d .conclusion { background: linear-gradient(135deg, rgba(94,94,215,0.08) 0%, rgba(169,226,228,0.15) 100%); border-radius: var(--border-radius); padding: 40px 36px; margin: 40px 0; text-align: center; }\n.dbi-art-b0224d .conclusion h2 { border: none; margin-top: 0; }\n.dbi-art-b0224d .conclusion p { font-size: 16px; max-width: 640px; margin: 0 auto 24px; }\n.dbi-art-b0224d .btn-cta { display: inline-block; background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; font-family: 'Montserrat', sans-serif; font-weight: 700; font-size: 15px; padding: 14px 32px; border-radius: 50px; text-decoration: none; box-shadow: 0 6px 20px rgba(94,94,215,0.3); transition: transform 0.2s, box-shadow 0.2s; }\n.dbi-art-b0224d .btn-cta:hover { transform: translateY(-3px); box-shadow: 0 10px 28px rgba(94,94,215,0.4); }\n.dbi-art-b0224d .article-footer { background: linear-gradient(135deg, var(--blue), var(--blue-dark)); color: white; padding: 40px 24px; text-align: center; }\n.dbi-art-b0224d .article-footer p { color: rgba(255,255,255,0.8); font-size: 14px; margin-bottom: 16px; }\n.dbi-art-b0224d .footer-links { display: flex; justify-content: center; gap: 20px; flex-wrap: wrap; }\n.dbi-art-b0224d .footer-links a { color: white; text-decoration: none; font-size: 13px; font-weight: 600; padding: 8px 18px; border: 1px solid rgba(255,255,255,0.3); border-radius: 50px; transition: background 0.2s; }\n.dbi-art-b0224d .footer-links a:hover { background: rgba(255,255,255,0.15); }\n@media (max-width: 640px) {\n.dbi-art-b0224d .cta-formation, .dbi-art-b0224d .cta-outil { flex-direction: column; }\n.dbi-art-b0224d .cards-grid { grid-template-columns: 1fr; }\n.dbi-art-b0224d .timeline::before { left: 20px; }\n}\n\n<\/style>\n<div class=\"dbi-art-b0224d\">\n<!-- \u2550\u2550 HERO \u2550\u2550 -->\n<header class=\"hero\">\n  <div class=\"hero-tag\">\ud83e\udde0 Neurological diseases \u00b7 Multiple sclerosis<\/div>\n  <h1>Multiple sclerosis: understand everything<br>about this neurological disease<\/h1>\n  <p class=\"hero-sub\">Causes, symptoms, progressive forms, diagnosis and management \u2014 a complete guide for patients, relatives and healthcare professionals<\/p>\n  <div class=\"hero-meta\">\n    <span>\ud83d\udcd6 Reading: ~22 min<\/span>\n    <span>\u2705 Updated 2026<\/span>\n    <span>\ud83d\udc69\u200d\u2695\ufe0f Patients, families &amp; caregivers<\/span>\n  <\/div>\n<\/header>\n\n<!-- \u2550\u2550 STATS \u2550\u2550 -->\n<div class=\"stats-bar\">\n  <div class=\"stats-grid\">\n    <div class=\"stat-item\">\n      <span class=\"stat-num\">120,000<\/span>\n      <span class=\"stat-label\">people affected in France<\/span>\n    <\/div>\n    <div class=\"stat-item\">\n      <span class=\"stat-num\">3,000<\/span>\n      <span class=\"stat-label\">new cases diagnosed each year<\/span>\n    <\/div>\n    <div class=\"stat-item\">\n      <span class=\"stat-num\">30 years<\/span>\n      <span class=\"stat-label\">average age at diagnosis<\/span>\n    <\/div>\n    <div class=\"stat-item\">\n      <span class=\"stat-num\">2\u00d7<\/span>\n      <span class=\"stat-label\">more common in women<\/span>\n    <\/div>\n  <\/div>\n<\/div>\n\n<!-- \u2550\u2550 CONTENT \u2550\u2550 -->\n<main class=\"container\">\n\n  <div class=\"intro-block\">\n    <p>Multiple sclerosis (MS) is one of the most common neurological diseases among young adults. A chronic autoimmune disease of the central nervous system, it affects approximately 120,000 people in France and still raises many questions, fears, and misconceptions today. This comprehensive guide aims to help you deeply understand what MS really is: its biological mechanisms, its multiple clinical faces, the challenges of diagnosis, the treatments available in 2026, and above all, the concrete resources to support patients and their loved ones on a daily basis.<\/p>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 1 \u2500\u2500 -->\n  <h2>1. What is multiple sclerosis? Definition and mechanisms<\/h2>\n\n  <p>The term \"multiple sclerosis\" may seem mysterious. It actually refers to a precise anatomical reality: <strong>plaques of demyelination<\/strong> \u2014 that is, areas where the myelin, the protective sheath of nerve fibers, has been damaged \u2014 scattered throughout the brain and spinal cord. These scars (sclerosis) give the disease its name.<\/p>\n\n  <h3>1.1 Myelin: understanding why it's central<\/h3>\n\n  <p>To understand MS, one must understand the role of myelin. This fatty substance surrounds axons (extensions of neurons) and acts as an insulating electrical cable: it accelerates and ensures the reliability of nerve impulse transmission. Without intact myelin, nerve signals slow down, disperse, or fail to reach their destination.<\/p>\n\n  <p>In MS, the immune system mistakenly attacks this myelin \u2014 this is the definition of an autoimmune disease. Immune cells (mainly T lymphocytes) cross the blood-brain barrier and cause inflammation that gradually destroys the myelin sheath, and sometimes the axons themselves. The result: disturbances in the transmission of nerve signals, which manifest as the very varied symptoms characteristic of MS.<\/p>\n<div class=\"highlight-box\">\n    <h4>\ud83e\uddec MS: an autoimmune disease, not contagious<\/h4>\n    <p>MS is <strong>not contagious<\/strong>, does not transmit from one person to another and is <strong>not directly hereditary<\/strong> in the strict sense. It results from a complex interaction between a genetic predisposition (several genes involved, including HLA-DRB1) and triggering environmental factors. Having a parent with MS increases the risk, but does not make it certain.<\/p>\n<\/div>\n\n<h3>1.2 Why \"plaques\"?<\/h3>\n\n<p>The term \"plaques\" refers to the visible lesions on MRI \u2014 areas of demyelination that appear as white spots on brain images. These plaques are <strong>disseminated in space<\/strong> (they are found in several places in the brain and spinal cord) and <strong>disseminated in time<\/strong> (they appear at different times). This double dissemination \u2014 spatial and temporal \u2014 actually forms the basis of the modern diagnosis of MS.<\/p>\n\n<!-- \u2500\u2500 SECTION 2 \u2500\u2500 -->\n<h2>2. The causes of MS: what research has identified<\/h2>\n\n<p>After decades of research, multiple sclerosis is now better understood, even though no single definitive cause has been identified. MS results from an interaction between genetic, immunological, and environmental factors.<\/p>\n\n<h3>2.1 Genetic factors<\/h3>\n\n<p>MS is not a genetic disease in the classical sense \u2014 there is no unique \"MS gene.\" However, a genetic predisposition is clearly established. The risk of developing MS is about 0.1% in the general population, but rises to 2-3% if a first-degree relative is affected, and to 25-30% in monozygotic twins (identical twins). More than 200 genetic variants have been associated with susceptibility to MS, most involved in the regulation of the immune system.<\/p>\n\n<h3>2.2 Environmental factors: the main suspects<\/h3>\n\n<div class=\"cards-grid\">\n    <div class=\"card\">\n      <div class=\"card-icon blue\">\u2600\ufe0f<\/div>\n      <h4>Vitamin D deficiency<\/h4>\n      <p>Vitamin D plays a major immunoregulatory role. Regions far from the equator, with less sunshine, have a significantly higher prevalence of MS. Studies show that low vitamin D levels increase the risk of MS and are associated with higher disease activity.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <div class=\"card-icon teal\">\ud83e\udda0<\/div>\n      <h4>Epstein-Barr Virus (EBV)<\/h4>\n      <p>Very strong recent studies (notably on millions of American military personnel) establish a strong link between infection with the EBV (responsible for mononucleosis) and the development of MS. This mechanism is the subject of intense research in 2026.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <div class=\"card-icon yellow\">\ud83d\udeac<\/div>\n      <h4>Smoking<\/h4>\n      <p>Tobacco is a recognized risk factor, which increases both the likelihood of developing MS and its rate of progression. It also reduces the effectiveness of immunomodulatory treatments.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <div class=\"card-icon pink\">\ud83e\uddeb<\/div>\n      <h4>Gut microbiome<\/h4>\n      <p>Disruptions of the gut microbiome (dysbiosis) have been observed in MS patients. The link between the gut-brain axis and autoimmune inflammation is a major research area that could open new therapeutic avenues.<\/p>\n    <\/div>\n<\/div>\n\n<div class=\"tip-box\">\n<div class=\"icon\">\ud83d\udca1<\/div>\n    <p><strong>The mystery of latitude:<\/strong> MS is significantly more common in Nordic countries (Scandinavia, Scotland, Canada) than in tropical countries. In France, the prevalence is higher in Alsace than in Corsica. This geographical distribution directs researchers towards sunlight, vitamin D, and infectious factors as keys to understanding the disease.<\/p>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 3 \u2500\u2500 -->\n  <h2>3. The different forms of MS<\/h2>\n\n  <p>MS is not a uniform disease. It presents in several evolving forms, which differ in their relapse profile, rate of progression, and therapeutic implications.<\/p>\n\n  <div class=\"table-wrap\">\n    <table>\n      <thead>\n        <tr>\n          <th>Form<\/th>\n          <th>Evolving profile<\/th>\n          <th>Frequency<\/th>\n          <th>Treatment<\/th>\n        <\/tr>\n      <\/thead>\n      <tbody>\n        <tr>\n          <td><strong>Relapsing-remitting MS (RRMS)<\/strong><\/td>\n          <td>Relapses with partial or total recovery between episodes<\/td>\n          <td><span class=\"badge badge-pink\">85% of cases at diagnosis<\/span><\/td>\n          <td>Very effective disease-modifying treatments available<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>Secondarily progressive MS (SPMS)<\/strong><\/td>\n          <td>Initial relapsing phase, then continuous progression with or without relapses<\/td>\n          <td><span class=\"badge badge-blue\">50% of RRMS after 10-15 years<\/span><\/td>\n          <td>Limited but expanding options<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>Primarily progressive MS (PPMS)<\/strong><\/td>\n          <td>Continuous progression from the start, without distinct relapses<\/td>\n          <td><span class=\"badge badge-yellow\">10-15% of cases<\/span><\/td>\n          <td>Ocrelizumab approved since 2018<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>Progressive-relapsing MS<\/strong><\/td>\n          <td>Continuous progression with superimposed relapses<\/td>\n          <td><span class=\"badge badge-teal\">Rare<\/span><\/td>\n          <td>Combined approach<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>Clinically isolated syndrome (CIS)<\/strong><\/td>\n          <td>First neurological episode, not yet established MS<\/td>\n          <td><span class=\"badge badge-blue\">Possible precursor<\/span><\/td>\n          <td>Monitoring and early treatment discussed<\/td>\n        <\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n<div class=\"warning-box\">\n    <p>\u26a0\ufe0f <strong>Benign MS: a concept to nuance.<\/strong> For a long time, \"benign MS\" was used to describe forms with few relapses and little disability over 10-15 years. This concept is now being questioned: long-term follow-up studies show that even seemingly benign forms can evolve into progressive disability, and that cognitive disorders may be present while mobility is intact.<\/p>\n<\/div>\n\n<!-- \u2500\u2500 SECTION 4 \u2500\u2500 -->\n<h2>4. Symptoms of multiple sclerosis<\/h2>\n\n<p>MS is often called \"the disease with a thousand faces\" as its symptoms are varied, unpredictable, and different from one person to another. They depend on the location of the plaques in the brain and spinal cord. Some are visible from the outside, while others \u2014 the \"invisible symptoms\" \u2014 are often unknown or misunderstood by those around.<\/p>\n\n<h3>4.1 Motor symptoms<\/h3>\n\n<p>Motor disorders are among the most visible manifestations of MS. They include <strong>weakness or paralysis<\/strong> of one or more limbs (hemiparesis, paraparesis), balance and coordination disorders (ataxia), spasms, and muscle spasticity, as well as intention tremors. These symptoms directly affect mobility, walking, and daily activities.<\/p>\n\n<h3>4.2 Sensory disorders<\/h3>\n\n<p>Tingling, numbness, burning sensations or tightness, neuropathic pain are part of the frequent sensory symptoms in MS. Lhermitte's sign \u2014 a sensation of electricity descending the spine when bending the neck \u2014 is characteristic of MS, even though it is not specific.<\/p>\n\n<h3>4.3 Visual disorders<\/h3>\n\n<p>Optic neuritis \u2014 inflammation of the optic nerve \u2014 is often the first sign of MS. It manifests as a decrease in unilateral visual acuity, pain with eye movement, and alteration of color vision. In most cases, recovery is good, but some sequelae may persist. Diplopia (double vision) due to involvement of the eye muscles is also common.<\/p>\n\n<div class=\"cards-grid\">\n    <div class=\"card\">\n      <div class=\"card-icon blue\">\ud83d\ude34<\/div>\n      <h4>Fatigue \u2014 the invisible symptom #1<\/h4>\n      <p>MS fatigue is unique: profound, overwhelming, not correlated with effort, it can occur suddenly even after a night of sleep. It affects 80% of patients and is often the most disabling symptom in daily life, yet little visible from the outside.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <div class=\"card-icon teal\">\ud83e\udde0<\/div>\n      <h4>Cognitive disorders<\/h4>\n      <p>50 to 70% of MS patients experience cognitive disorders: slowing of information processing, difficulties with episodic and working memory, concentration issues, and executive function problems. These symptoms are often poorly recognized but have a significant impact on professional and social life.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <div class=\"card-icon yellow\">\ud83c\udf21\ufe0f<\/div>\n      <h4>Uhthoff's phenomenon<\/h4>\n      <p>The temporary worsening of symptoms in heat (hot bath, fever, intense exercise) is characteristic of MS. It is due to the increased sensitivity of demyelinated fibers to heat. This phenomenon is not a relapse \u2014 symptoms regress with cooling.<\/p>\n    <\/div>\n    <div class=\"card\">\n<div class=\"card-icon pink\">\ud83d\udebd<\/div>\n      <h4>Bladder and sphincter disorders<\/h4>\n      <p>Urinary urgency, incontinence, difficulties urinating, constipation \u2014 bladder and sphincter disorders affect 70 to 80% of patients at some point in their illness. They have a major impact on quality of life and are often addressed late due to embarrassment.<\/p>\n    <\/div>\n  <\/div>\n\n  <div class=\"cta-outil\">\n    <div class=\"cta-icon\">\ud83c\udf21\ufe0f<\/div>\n    <div>\n      <h4>DYNSEO Emotion Thermometer<\/h4>\n      <p>MS is often accompanied by emotional fluctuations that are difficult to verbalize. The emotion thermometer allows patients and caregivers to identify and communicate the emotional state of the day, thus facilitating mutual understanding and therapeutic follow-up.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/nos-outils\/thermometre-des-emotions\/\" class=\"btn-blue\">Discover the tool<\/a>\n    <\/div>\n  <\/div>\n\n  <h3>4.4 Psychological and emotional symptoms<\/h3>\n\n  <p>MS does not only affect the body. Mood disorders \u2014 depression, anxiety, emotional lability \u2014 are common and multifactorial: they can result directly from brain lesions in the areas of emotional regulation, from the psychological reaction to a chronic disabling illness, or from the side effects of certain treatments.<\/p>\n\n  <p>Depression affects about 50% of MS patients during their lifetime \u2014 a rate significantly higher than that observed in other comparable chronic diseases. It must be systematically screened and treated, as it significantly worsens quality of life and can impact adherence to treatments.<\/p>\n\n  <!-- \u2500\u2500 SECTION 5 \u2500\u2500 -->\n  <h2>5. What is an MS relapse?<\/h2>\n\n  <p>In relapsing-remitting MS, the disease progresses through <strong>relapses<\/strong> \u2014 episodes of onset or worsening of neurological symptoms. Understanding what a relapse is, how to recognize it, and how to react is essential for patients and their loved ones.<\/p>\n\n  <div class=\"numbered-card\">\n    <div class=\"num-badge\">\ud83d\udccb<\/div>\n    <div class=\"num-content\">\n      <h4>Definition of a relapse<\/h4>\n      <p>A relapse is defined as the onset or worsening of neurological symptoms lasting at least 24 hours, in the absence of fever or infection, separated by at least 30 days from the previous relapse. It corresponds to new active inflammation in the central nervous system.<\/p>\n    <\/div>\n  <\/div>\n  <div class=\"numbered-card\">\n    <div class=\"num-badge\">\u23f1\ufe0f<\/div>\n    <div class=\"num-content\">\n      <h4>Duration and recovery<\/h4>\n      <p>A relapse generally lasts from a few days to a few weeks. Recovery is often good, especially in the early years of the disease, but can be partial. Each relapse can leave varying sequelae \u2014 this is why early treatment of severe relapses is important.<\/p>\n    <\/div>\n  <\/div>\n  <div class=\"numbered-card\">\n    <div class=\"num-badge\">\ud83d\udea8<\/div>\n<div class=\"num-content\">\n      <h4>Treatment of relapses<\/h4>\n      <p>Severe relapses are treated with high-dose corticosteroid infusions (methylprednisolone), which accelerate recovery without altering the long-term prognosis. This treatment should only be used for truly disabling relapses.<\/p>\n    <\/div>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 6 \u2500\u2500 -->\n  <h2>6. The diagnosis of multiple sclerosis<\/h2>\n\n  <p>The diagnosis of MS is a pivotal moment in a person's life. It currently relies on the <strong>McDonald criteria 2017<\/strong>, which integrate clinical, MRI, and biological data to make the diagnosis with maximum precision and minimum delay.<\/p>\n\n  <h3>6.1 MRI: the key examination<\/h3>\n\n  <p>Cerebral and spinal MRI is the reference examination in MS. It allows visualization of demyelination plaques, localization, dating (active lesions enhance after gadolinium injection), and monitoring their evolution. A brain with \"black hole\" lesions (old plaques) and recent lesions indicates active disease.<\/p>\n\n  <h3>6.2 Lumbar puncture and evoked potentials<\/h3>\n\n  <p>The lumbar puncture, which analyzes cerebrospinal fluid (CSF), can reveal oligoclonal bands of IgG \u2014 present in 85-90% of MS cases \u2014 and other inflammatory markers. Visual, auditory, or sensory evoked potentials measure nerve conduction speed and can detect clinically silent lesions.<\/p>\n\n  <div class=\"cta-formation\">\n    <div class=\"cta-icon\">\ud83c\udf93<\/div>\n    <div>\n      <h4>Training \u2014 Understanding MS: essential guide for relatives<\/h4>\n      <p>An accessible and supportive training to help relatives understand the disease, its mechanisms, symptoms, and evolution \u2014 to better support without exhausting themselves.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/courses\/comprendre-la-sclerose-en-plaques-guide-essentiel-pour-les-proches\/\" class=\"btn-white\">Access the training \u2192<\/a>\n    <\/div>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 7 \u2500\u2500 -->\n  <h2>7. Treatments for multiple sclerosis in 2026<\/h2>\n\n  <p>The therapeutic management of MS has significantly progressed since the 1990s. Today, a wide arsenal of medications allows for reducing the frequency of relapses, slowing progression, and preventing lesions. However, there is still no curative treatment.<\/p>\n\n  <h3>7.1 Disease-modifying treatments (DMT)<\/h3>\n\n  <p>Disease-Modifying Therapies (DMT) aim to reduce inflammatory activity and prevent new relapses. They are divided into three levels of efficacy:<\/p>\n<div class=\"table-wrap\">\n    <table>\n      <thead>\n        <tr>\n          <th>Level<\/th>\n          <th>Main molecules<\/th>\n          <th>Effectiveness on outbreaks<\/th>\n          <th>Administration<\/th>\n        <\/tr>\n      <\/thead>\n      <tbody>\n        <tr>\n          <td><strong>1st line (moderate)<\/strong><\/td>\n          <td>Beta interferon, Glatiramer acetate, Dimethyl fumarate, Teriflunomide<\/td>\n          <td><span class=\"badge badge-yellow\">-30 to -50 %<\/span><\/td>\n          <td>Injectable or oral<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>2nd line (high effectiveness)<\/strong><\/td>\n          <td>Natalizumab, Fingolimod, Siponimod, Ozanimod<\/td>\n          <td><span class=\"badge badge-blue\">-60 to -70 %<\/span><\/td>\n          <td>Injectable or oral<\/td>\n        <\/tr>\n        <tr>\n          <td><strong>3rd line (very high effectiveness)<\/strong><\/td>\n          <td>Alemtuzumab, Ocrelizumab, Ofatumumab, Cladribine<\/td>\n          <td><span class=\"badge badge-pink\">-70 to -90 %<\/span><\/td>\n          <td>Infusion or oral<\/td>\n        <\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <h3>7.2 Rehabilitation and non-drug management<\/h3>\n\n  <p>Rehabilitation plays a central role in the management of MS. Physiotherapy, occupational therapy, speech therapy (for swallowing or speech disorders), neuropsychology, psychology \u2014 each specialty contributes to maintaining functional abilities and quality of life. Adapted physical activity, long discouraged for fear of worsening symptoms, is now recognized as beneficial at all stages of the disease.<\/p>\n\n  <div class=\"cta-outil\">\n    <div class=\"cta-icon\">\ud83d\udccb<\/div>\n    <div>\n      <h4>DYNSEO session follow-up sheet<\/h4>\n      <p>The session follow-up sheet allows healthcare professionals (physiotherapist, occupational therapist, psychomotor therapist) to track the exercises performed, the progress observed, and the goals for the next session \u2014 a valuable continuity tool in the follow-up of MS patients.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/nos-outils\/fiche-suivi-seance\/\" class=\"btn-blue\">Download the sheet<\/a>\n    <\/div>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 8 \u2500\u2500 -->\n  <h2>8. Cognitive disorders in MS: the hidden side of the disease<\/h2>\n\n  <p>Cognitive disorders are one of the most poorly recognized and least well-managed manifestations of MS. Yet, they affect more than half of patients and have a considerable impact on professional, family, and social life.<\/p>\n\n  <h3>8.1 What cognitive disorders in MS?<\/h3>\n\n  <div class=\"profil-grid\">\n    <div class=\"profil-card\">\n      <span class=\"emoji\">\u26a1<\/span>\n      <h4>Cognitive slowing<\/h4>\n      <p>Slower information processing. Complex tasks take longer, even if performed correctly.<\/p>\n    <\/div>\n    <div class=\"profil-card\">\n      <span class=\"emoji\">\ud83d\udcbe<\/span>\n      <h4>Episodic memory<\/h4>\n      <p>Difficulties in memorizing new information and retrieving it later. Procedural memory is often better preserved.<\/p>\n    <\/div>\n    <div class=\"profil-card\">\n      <span class=\"emoji\">\ud83c\udfaf<\/span>\n      <h4>Sustained attention<\/h4>\n      <p>Difficulties in maintaining concentration on a long task, filtering out distractors, doing two things at once.<\/p>\n    <\/div>\n<div class=\"profil-card\">\n      <span class=\"emoji\">\ud83d\uddc2\ufe0f<\/span>\n      <h4>Executive functions<\/h4>\n      <p>Planning, organization, mental flexibility, and decision-making difficulties under time pressure.<\/p>\n    <\/div>\n  <\/div>\n\n  <h3>8.2 Cognitive stimulation: an essential lever<\/h3>\n\n  <p>Regular cognitive stimulation is now recognized as a lever for maintaining intellectual capacities in MS. It does not heal existing lesions, but it promotes brain plasticity \u2014 the brain's ability to create new compensatory circuits \u2014 and can slow cognitive decline.<\/p>\n\n  <p>The <strong><a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\" style=\"color: var(--blue);\">CLINT<\/a><\/strong> app from DYNSEO is specially designed for adults with cognitive disorders, particularly in the context of neurological pathologies like MS. Its activities \u2014 memory, attention, language, logic \u2014 are adapted in difficulty, progressive, and accessible even for individuals experiencing significant cognitive fatigue.<\/p>\n\n  <div class=\"cta-outil\">\n    <div class=\"cta-icon\">\ud83d\udcca<\/div>\n    <div>\n      <h4>DYNSEO Motivation Chart<\/h4>\n      <p>Maintaining regularity in cognitive stimulation can be difficult with fatigue related to MS. The motivation chart helps visualize goals, celebrate progress, and maintain engagement in cognitive activities on a daily basis.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/nos-outils\/tableau-de-motivation\/\" class=\"btn-blue\">Access the chart<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"cta-formation\">\n    <div class=\"cta-icon\">\ud83c\udf93<\/div>\n    <div>\n      <h4>Training \u2014 Fatigue and cognitive disorders in MS<\/h4>\n      <p>Understanding the mechanisms of fatigue and cognitive disorders in MS, identifying compensatory strategies and suitable stimulation tools \u2014 for patients as well as for relatives and caregivers.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/courses\/fatigue-et-troubles-cognitifs-dans-la-sep-ce-que-les-familles-peuvent-faire\/\" class=\"btn-white\">Discover the training \u2192<\/a>\n    <\/div>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 9 \u2500\u2500 -->\n  <h2>9. Living with MS: daily life, work, and relationships<\/h2>\n\n  <p>MS is a disease that settles into daily life. It disrupts projects, relationships, and professional and personal identity. Understanding these dimensions is essential to provide comprehensive and humane support.<\/p>\n\n  <h3>9.1 MS and professional life<\/h3>\n\n  <p>MS primarily affects young adults in full professional activity. Fatigue, cognitive disorders, unpredictable flare-ups, frequent medical appointments \u2014 maintaining professional activity often constitutes a major challenge. Yet, working remains possible and desirable for the vast majority of patients, especially with suitable accommodations.<\/p>\n\n  <div class=\"two-cols\">\n    <div class=\"col-block\">\n      <h4>\ud83c\udfe2 Workplace accommodations<\/h4>\n      <ul>\n        <li>Partial or total telecommuting<\/li>\n        <li>Adjusted hours (morning fatigue or nap)<\/li>\n        <li>Adapted position (ergonomic desk, chair)<\/li>\n        <li>Disability recognition for access to AGEFIPH aids<\/li>\n        <li>Therapeutic part-time work if necessary<\/li>\n        <li>Cognitive assistance software<\/li>\n      <\/ul>\n    <\/div>\n<div class=\"col-block\">\n      <h4>\ud83d\udcac To tell or not to tell the employer?<\/h4>\n      <ul>\n        <li>No legal obligation to disclose MS<\/li>\n        <li>The occupational physician, medical confidentiality guaranteed<\/li>\n        <li>Disability recognition possible without revealing the diagnosis<\/li>\n        <li>MS France Association: legal advice<\/li>\n        <li>Cap Emploi: tailored professional support<\/li>\n        <li>Each situation is unique \u2014 personal decision<\/li>\n      <\/ul>\n    <\/div>\n  <\/div>\n\n  <h3>9.2 MS, couple and surroundings<\/h3>\n\n  <p>MS affects the surroundings as much as the patient. Loved ones \u2014 especially the partner \u2014 may find themselves in an unchosen caregiver role, with the risks of burnout that this entails. Communication within the couple transforms, sometimes leading to a rupture of the intimate balance.<\/p>\n\n  <p>Expressing what one feels, naming the invisible fatigue, discussing fears and mutual expectations without waiting for a crisis \u2014 this is the challenge that many couples facing MS take on. Psychological support for both members of the couple is often valuable.<\/p>\n\n  <div class=\"cta-outil\">\n    <div class=\"cta-icon\">\ud83d\udcca<\/div>\n    <div>\n      <h4>3-column table \u2014 structuring thoughts and emotions<\/h4>\n      <p>The 3-column table from DYNSEO is a tool for cognitive and emotional structuring. It helps organize thoughts, identify obstacles and solutions \u2014 particularly useful for MS patients facing planning and prioritization difficulties.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/nos-outils\/tableau-3-colonnes\/\" class=\"btn-blue\">Use the tool<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"cta-formation\">\n    <div class=\"cta-icon\">\ud83c\udf93<\/div>\n    <div>\n      <h4>Training \u2014 Living with long-term MS: caregiver, couple, and future<\/h4>\n      <p>A training designed for caregivers and couples: understanding the impact of MS on relational dynamics, preventing caregiver burnout, and building a shared life project despite the disease.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/courses\/vivre-avec-la-sep-au-long-cours-aidant-couple-et-avenir\/\" class=\"btn-white\">Access the training \u2192<\/a>\n    <\/div>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 10 \u2500\u2500 -->\n  <h2>10. MS in institutions: supporting advanced forms<\/h2>\n\n  <p>In the progressive or advanced forms of MS, some patients are cared for in medico-social establishments (Nursing home, MAS, FAM) or benefit from intensive home care. Support in these contexts requires specific training for healthcare professionals.<\/p>\n\n  <p>Healthcare providers facing MS in institutions must understand the particularities of the disease: the variability of symptoms from day to day, the impact of heat on capacities, the cognitive fatigue that is not always visible, the often underestimated bladder and sphincter disorders, and the central psychological dimension of support.<\/p>\n\n  <div class=\"cta-formation\">\n    <div class=\"cta-icon\">\ud83c\udf93<\/div>\n    <div>\n      <h4>Training \u2014 MS in institutions: understanding and adapting practice<\/h4>\n      <p>A training dedicated to healthcare professionals who support MS patients in institutions: understanding the specifics of the disease, adapting care, preventing complications, and maintaining autonomy as long as possible.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/courses\/sclerose-en-plaques-en-etablissement-comprendre-la-maladie-et-adapter-sa-pratique-professionnelle\/\" class=\"btn-white\">Discover the training \u2192<\/a>\n    <\/div>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 11 \u2500\u2500 -->\n  <h2>11. Maintaining autonomy: strategies and practical tools<\/h2>\n\n  <p>Preserving autonomy is a central objective in supporting MS. This involves home adaptations, the use of technical aids, regular cognitive stimulation, and psychological support. But it also involves therapeutic education for the patient that allows them to understand their disease, recognize warning signs, and adapt their lifestyle.<\/p>\n\n  <h3>11.1 Adapting the home and daily life<\/h3>\n<div class=\"checklist\">\n    <li>Grab bars in the bathroom and stairs to prevent falls<\/li>\n    <li>Shower seat and flexible showerhead to manage fatigue and balance<\/li>\n    <li>Organization of the kitchen with suitable utensils and accessible work surface<\/li>\n    <li>Sufficient lighting to compensate for any visual disorders<\/li>\n    <li>Fan or air conditioner to avoid overheating (Uhthoff phenomenon)<\/li>\n    <li>Reminder and organization applications to compensate for memory disorders<\/li>\n    <li>Visual schedule displayed to structure days and reduce cognitive load<\/li>\n    <li>Electric scooter or wheelchair for mobility in case of significant fatigue<\/li>\n  <\/div>\n\n  <h3>11.2 Cognitive stimulation in daily life<\/h3>\n\n  <p>Regular cognitive exercises \u2014 reading, puzzles, strategy games, manual activities \u2014 help maintain brain plasticity and preserve intellectual abilities in MS. Digital stimulation programs like the <strong><a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\" style=\"color: var(--blue);\">CLINT<\/a><\/strong> app from DYNSEO offer structured, progressive, and accessible stimulation even on days of significant fatigue.<\/p>\n\n  <p>DYNSEO also offers a complete suite of <strong><a href=\"https:\/\/www.dynseo.com\/nos-tests\/\" style=\"color: var(--blue);\">online cognitive tests<\/a><\/strong> that allow for regular assessment of cognitive functions \u2014 memory, attention, processing speed \u2014 and early detection of any potential changes. These tools, used in conjunction with neuropsychological monitoring, provide a valuable dashboard for both the patient and the care team.<\/p>\n\n  <div class=\"cta-formation\">\n<div class=\"cta-icon\">\ud83c\udf93<\/div>\n    <div>\n      <h4>Training \u2014 MS and daily life: maintaining autonomy<\/h4>\n      <p>All the practical strategies to adapt daily life to MS, prevent complications, manage fatigue, and maintain autonomy for as long as possible \u2014 for patients and caregivers.<\/p>\n      <a href=\"https:\/\/www.dynseo.com\/courses\/sep-et-vie-quotidienne-maintenir-lautonomie-et-prevenir-les-complications\/\" class=\"btn-white\">Access the training \u2192<\/a>\n    <\/div>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 12 \u2500\u2500 -->\n  <h2>12. Research on MS in 2026: concrete hopes<\/h2>\n\n  <p>MS is one of the neurological diseases where research is progressing the fastest. In 2026, several research avenues open up truly promising perspectives for patients.<\/p>\n\n  <h3>12.1 Remyelination therapies<\/h3>\n\n  <p>So far, available treatments mainly act on inflammation to prevent new lesions. But they do not allow for the repair of already destroyed myelin. Remyelination therapies \u2014 which aim to stimulate precursor cells of oligodendrocytes to rebuild the damaged myelin sheath \u2014 represent the next great hope. Several molecules are in advanced clinical trials.<\/p>\n\n  <h3>12.2 Neuroprotection<\/h3>\n\n  <p>Alongside remyelination, neuroprotective therapies seek to preserve axons from damage caused by chronic inflammation. The progression of disability in progressive forms is largely related to irreversible axonal loss \u2014 this is the aspect that neuroprotective therapies aim to prevent.<\/p>\n\n  <h3>12.3 The role of the microbiome and new therapeutic targets<\/h3>\n\n  <p>The growing understanding of the role of the gut microbiome in MS paves the way for unprecedented therapeutic approaches: targeted probiotics, anti-inflammatory diets, and even fecal microbiota transplantation in research contexts. These experimental avenues illustrate the paradigm shift towards a more systemic view of the disease.<\/p>\n\n  <div class=\"tip-box\">\n    <div class=\"icon\">\ud83d\udd2c<\/div>\n    <p><strong>The EBV-MS link:<\/strong> The very strong demonstration of the link between Epstein-Barr virus infection and the subsequent development of MS has rekindled hopes for a preventive vaccine. If an anti-EBV vaccine proves effective in preventing mononucleosis, it could also reduce the incidence of MS \u2014 a prospect that mobilizes several global research teams.<\/p>\n  <\/div>\n\n  <!-- \u2500\u2500 SECTION 13 \u2500\u2500 -->\n  <h2>13. Resources, associations, and support for MS patients<\/h2>\n\n  <p>Being diagnosed with MS means joining a community of patients, loved ones, and professionals committed to fighting the disease. Many resources exist to ensure you do not go through this ordeal alone.<\/p>\n\n  <h3>13.1 Leading associations in France<\/h3>\n\n  <div class=\"cards-grid\">\n    <div class=\"card\">\n      <div class=\"card-icon blue\">\ud83c\udfdb\ufe0f<\/div>\n      <h4>ARSEP<\/h4>\n      <p>The Foundation for Research Aid on MS funds research and publishes validated medical information. It organizes fundraising events and provides educational resources for patients and their families.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <div class=\"card-icon teal\">\ud83e\udd1d<\/div>\n      <h4>MS France (formerly LFSEP)<\/h4>\n      <p>The French League Against Multiple Sclerosis supports patients in their administrative and social processes, offers local support groups, and provides legal and professional assistance.<\/p>\n    <\/div>\n    <div class=\"card\">\n<div class=\"card-icon yellow\">\ud83d\udc68\u200d\u2695\ufe0f<\/div>\n      <h4>OFSEP<\/h4>\n      <p>The French Observatory of MS is a national cohort that follows thousands of patients over time. Participation in OFSEP contributes to research and allows patients to benefit from enhanced monitoring in expert centers.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <div class=\"card-icon pink\">\ud83d\udcf1<\/div>\n      <h4>Monitoring Applications<\/h4>\n      <p>Dedicated applications allow patients to record their symptoms, fatigue levels, relapses, and treatments. This digital health journal is valuable during neurological consultations.<\/p>\n    <\/div>\n  <\/div>\n\n  <h3>13.2 Patient Therapeutic Education (PTE)<\/h3>\n\n  <p>Patient therapeutic education is a recognized right for people with chronic diseases. For MS patients, PTE programs are offered in reference centers: they learn to understand their disease, manage fatigue, recognize relapses, adapt their lifestyle, and communicate with caregivers. These programs significantly improve treatment adherence and quality of life.<\/p>\n\n  <p>DYNSEO's online training complements these initiatives by providing flexible and accessible access to quality information, whether for the patients themselves, their relatives, or the healthcare professionals who support them. The training <strong><a href=\"https:\/\/www.dynseo.com\/courses\/comprendre-la-sclerose-en-plaques-guide-essentiel-pour-les-proches\/\" style=\"color: var(--blue);\">Essential Guide for Relatives<\/a><\/strong> is particularly suitable for families looking to understand without getting lost in medical jargon.<\/p>\n<div class=\"quote-box\">\n    <p>\u00ab Understanding MS is not resigning oneself to the disease. It is giving oneself the means to live with it differently \u2014 with more serenity, more anticipation, and more humanity in the caregiver-patient relationship. \u00bb<\/p>\n    <cite>\u2014 Perspective of multidisciplinary teams in neurology<\/cite>\n  <\/div>\n\n  <h3>13.3 Nutrition, lifestyle, and psychological support<\/h3>\n\n  <p>If no diet has been scientifically proven as a treatment for MS, several data converge on the importance of an anti-inflammatory diet. The Mediterranean diet \u2014 rich in vegetables, fruits, fatty fish, olive oil, and legumes \u2014 is associated with better neurological health. Vitamin D supplementation is widely recommended for MS patients in consultation with the neurologist, as many patients have documented deficiencies. Stress management, quality sleep, and adapted physical activity are the other pillars of a favorable lifestyle.<\/p>\n\n  <p>Psychological support is an essential component of the overall management of MS, not a luxury. Living with an unpredictable chronic illness generates a real psychological burden: mourning for the life before, fear of the future, uncertainty about the progression, questioning one's professional and personal identity. Neuropsychologists play a particularly important role in supporting cognitive disorders related to MS: they precisely assess the cognitive profile, propose suitable compensation strategies, and assist the patient in managing their daily difficulties. In parallel, the regular use of cognitive stimulation tools like the <strong><a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\" style=\"color: var(--blue);\">CLINT<\/a><\/strong> app from DYNSEO helps maintain structured cognitive activity between professional follow-up sessions.<\/p>\n\n  <p>Finally, the online cognitive tests offered by DYNSEO on the <strong><a href=\"https:\/\/www.dynseo.com\/nos-tests\/\" style=\"color: var(--blue);\">our-tests<\/a><\/strong> page are a valuable monitoring tool: they allow the patient and their care team to track the evolution of cognitive functions over time, to detect any deterioration early, and to adjust stimulation programs accordingly. This proactive approach, combining medical follow-up and self-management, is at the heart of the new way to support MS in 2026.<\/p>\n<div class=\"highlight-box\">\n    <h4>\ud83c\udf1f The essential message for patients and their loved ones<\/h4>\n    <p>MS is a serious disease that deserves serious care. But it does not define a person in their entirety. Tens of thousands of people with MS lead active professional lives, fulfilling relationships, family projects, and rich community engagements. The secret: to inform oneself without drowning, to surround oneself without isolating, to care for oneself without reducing oneself to their illness. DYNSEO supports this approach with accessible training, practical tools, and a caring philosophy: every person deserves to be supported with the right tools, at the right time, at their own pace.<\/p>\n<\/div>\n\n<p>It is important to emphasize that MS affects people in the prime of their lives, often in the midst of building their life \u2014 professional, family, personal. This context makes psychological, social, and practical support even more crucial. Loved ones, caregivers, and employers have a decisive role to play so that people with MS can continue to thrive, contribute, and envision the future. Informing, training, equipping, and supporting: this is the mission that DYNSEO pursues through its training, free tools, and cognitive stimulation applications, in service of patients and all those around them. Understanding of MS progresses each year, and with it, hopes for increasingly effective treatments to preserve quality of life and slow down disability. Staying informed, active, and surrounded remains the best strategy against this complex but increasingly manageable disease.<\/p>\n<!-- \u2500\u2500 CONCLUSION \u2500\u2500 -->\n<div class=\"conclusion\">\n    <h2>What to remember about MS<\/h2>\n    <p>Multiple sclerosis is a complex, unpredictable disease, but it is increasingly well understood and treated. Early diagnosis, multidisciplinary care, and an adapted life allow the vast majority of patients to maintain their quality of life for a long time. MS is not a life on hold \u2014 it is a reinvented life, with the right tools and the right supporters by its side.<\/p>\n    <a href=\"https:\/\/www.dynseo.com\/courses\/comprendre-la-sclerose-en-plaques-guide-essentiel-pour-les-proches\/\" class=\"btn-cta\">Explore DYNSEO's MS training \u2192<\/a>\n<\/div>\n\n<\/main>\n\n<!-- \u2550\u2550 FAQ \u2550\u2550 -->\n<section class=\"faq-section\">\n<div class=\"container\">\n    <h2>FAQ \u2014 Frequently Asked Questions about Multiple Sclerosis<\/h2>\n\n    <div class=\"faq-item\">\n      <h4><span>Q1<\/span> Is multiple sclerosis fatal?<\/h4>\n      <p>MS only slightly reduces life expectancy in the vast majority of cases \u2014 by 5 to 10 years according to the most recent studies, a gap that tends to narrow thanks to modern treatments. It is not a fatal disease in the short term. However, very severe forms and complications (recurrent urinary infections, pneumonia related to swallowing disorders) can be serious. MS can also lead to significant disability, which justifies early and active management.<\/p>\n    <\/div>\n\n    <div class=\"faq-item\">\n      <h4><span>Q2<\/span> Can you get pregnant when you have MS?<\/h4>\n      <p>Yes, and pregnancy even has a protective effect on MS: relapses are less frequent during pregnancy, especially in the third trimester. However, the risk of relapse increases in the 3-6 months after childbirth. A pregnancy in a woman with MS should be planned and discussed with the neurologist, particularly to adjust the baseline treatment before conception and after childbirth. MS does not prevent becoming a mother.<\/p>\n    <\/div>\n\n    <div class=\"faq-item\">\n      <h4><span>Q3<\/span> What is the difference between a relapse and a pseudo-relapse?<\/h4>\n      <p>A pseudo-relapse (or false relapse) is a temporary worsening of already existing symptoms, without new active inflammatory lesions. It is often triggered by heat (Uhthoff's phenomenon), an infection, a feverish state, or great fatigue. A true relapse involves new symptoms or a clear worsening of old symptoms, lasting more than 24 hours, without fever. The distinction is important because true relapses may require treatment with corticosteroids, while pseudo-relapses do not.<\/p>\n    <\/div>\n\n    <div class=\"faq-item\">\n      <h4><span>Q4<\/span> Can you engage in sports activities with MS?<\/h4>\n      <p>Not only is it possible, but it is highly recommended. Regular and adapted physical activity improves fatigue, muscle strength, balance, sleep quality, mood, and even cognitive functions in MS. Swimming (in cool water), yoga, Pilates, indoor cycling, and Nordic walking are particularly well-suited. Intense efforts that significantly raise body temperature should be avoided. An adapted physical activity program (APA) with a professional is ideal.<\/p>\n    <\/div>\n\n    <div class=\"faq-item\">\n      <h4><span>Q5<\/span> How to help a loved one with MS without exhausting yourself?<\/h4>\n      <p>Helping a loved one with MS is a valuable but demanding commitment. To avoid burnout, it is essential to accept external help (home services, caregiver relief), maintain personal spaces and activities for oneself, participate in support groups for caregivers, and educate oneself to better understand the disease. DYNSEO offers training dedicated to caregivers and couples: <a href=\"https:\/\/www.dynseo.com\/courses\/vivre-avec-la-sep-au-long-cours-aidant-couple-et-avenir\/\" style=\"color: var(--blue);\">Living with MS in the long term<\/a>. Taking care of oneself is not abandoning the other \u2014 it is the condition for being able to continue supporting them.<\/p>\n    <\/div>\n  <\/div>\n<\/section>\n\n<!-- \u2550\u2550 FOOTER \u2550\u2550 -->\n<footer class=\"article-footer\">\n  <p>Discover all DYNSEO resources to support neurological diseases<\/p>\n  <div class=\"footer-links\">\n    <a href=\"https:\/\/www.dynseo.com\/nos-formations\/\">Our MS training<\/a>\n    <a href=\"https:\/\/www.dynseo.com\/nos-outils\/\">Free tools<\/a>\n    <a href=\"https:\/\/www.dynseo.com\/nos-tests\/\">Cognitive tests<\/a>\n    <a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/clint-brain-games-for-adults\/\">CLINT App<\/a>\n    <a href=\"https:\/\/www.dynseo.com\/en\/brain-games-apps\/scarlett-brain-games-for-seniors\/\">SCARLETT App<\/a>\n  <\/div>\n<\/footer>\n<\/div>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":"","footnotes":""},"categories":[2915],"tags":[],"class_list":["post-702221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-conseils-des-coachs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Multiple Sclerosis: Everything You Need to Know About This Neurological Disease - DYNSEO - Educational apps &amp; brain training apps for all<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease - DYNSEO - Educational apps &amp; brain training apps for all\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"DYNSEO - Educational apps &amp; brain training apps for all\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T11:51:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T11:56:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.dynseo.com\/wp-content\/uploads\/2023\/03\/telemedecine-ehpad.png\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DYNSEO\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DYNSEO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"23 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/\"},\"author\":{\"name\":\"DYNSEO\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/person\\\/78ef63df2ee64e0989bc68f8401b38d6\"},\"headline\":\"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease\",\"datePublished\":\"2026-06-12T11:51:13+00:00\",\"dateModified\":\"2026-06-12T11:56:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/\"},\"wordCount\":4559,\"publisher\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/telemedecine-ehpad.png\",\"articleSection\":[\"Les conseils des coachs\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/\",\"name\":\"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease - DYNSEO - Educational apps &amp; brain training apps for all\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/telemedecine-ehpad.png\",\"datePublished\":\"2026-06-12T11:51:13+00:00\",\"dateModified\":\"2026-06-12T11:56:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/telemedecine-ehpad.png\",\"contentUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/telemedecine-ehpad.png\",\"width\":500,\"height\":500,\"caption\":\"Empowering Young Minds: Discover the Power of Interactive Learning Apps\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\",\"name\":\"Jeux de m\u00e9moire et stimulation cognitive\",\"description\":\"DYNSEO, and your brain is a new hero!\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\",\"name\":\"DYNSEO\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-dynseo-new.png\",\"contentUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-dynseo-new.png\",\"width\":5073,\"height\":1397,\"caption\":\"DYNSEO\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/person\\\/78ef63df2ee64e0989bc68f8401b38d6\",\"name\":\"DYNSEO\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/author\\\/justine\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease - DYNSEO - Educational apps &amp; brain training apps for all","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/","og_locale":"en_US","og_type":"article","og_title":"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease - DYNSEO - Educational apps &amp; brain training apps for all","og_url":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/","og_site_name":"DYNSEO - Educational apps &amp; brain training apps for all","article_published_time":"2026-06-12T11:51:13+00:00","article_modified_time":"2026-06-12T11:56:19+00:00","og_image":[{"width":500,"height":500,"url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2023\/03\/telemedecine-ehpad.png","type":"image\/png"}],"author":"DYNSEO","twitter_misc":{"Written by":"DYNSEO","Est. reading time":"23 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/#article","isPartOf":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/"},"author":{"name":"DYNSEO","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/person\/78ef63df2ee64e0989bc68f8401b38d6"},"headline":"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease","datePublished":"2026-06-12T11:51:13+00:00","dateModified":"2026-06-12T11:56:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/"},"wordCount":4559,"publisher":{"@id":"https:\/\/www.dynseo.com\/en\/#organization"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2023\/03\/telemedecine-ehpad.png","articleSection":["Les conseils des coachs"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/","url":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/","name":"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease - DYNSEO - Educational apps &amp; brain training apps for all","isPartOf":{"@id":"https:\/\/www.dynseo.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2023\/03\/telemedecine-ehpad.png","datePublished":"2026-06-12T11:51:13+00:00","dateModified":"2026-06-12T11:56:19+00:00","breadcrumb":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/#primaryimage","url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2023\/03\/telemedecine-ehpad.png","contentUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2023\/03\/telemedecine-ehpad.png","width":500,"height":500,"caption":"Empowering Young Minds: Discover the Power of Interactive Learning Apps"},{"@type":"BreadcrumbList","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-everything-you-need-to-know-about-this-neurological-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.dynseo.com\/en\/"},{"@type":"ListItem","position":2,"name":"Multiple Sclerosis: Everything You Need to Know About This Neurological Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.dynseo.com\/en\/#website","url":"https:\/\/www.dynseo.com\/en\/","name":"Jeux de m\u00e9moire et stimulation cognitive","description":"DYNSEO, and your brain is a new hero!","publisher":{"@id":"https:\/\/www.dynseo.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dynseo.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.dynseo.com\/en\/#organization","name":"DYNSEO","url":"https:\/\/www.dynseo.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2022\/05\/logo-dynseo-new.png","contentUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2022\/05\/logo-dynseo-new.png","width":5073,"height":1397,"caption":"DYNSEO"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/person\/78ef63df2ee64e0989bc68f8401b38d6","name":"DYNSEO","url":"https:\/\/www.dynseo.com\/en\/author\/justine\/"}]}},"_links":{"self":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/702221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/comments?post=702221"}],"version-history":[{"count":16,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/702221\/revisions"}],"predecessor-version":[{"id":702237,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/702221\/revisions\/702237"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/media\/100456"}],"wp:attachment":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/media?parent=702221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/categories?post=702221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/tags?post=702221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}